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Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by 
the formation of autoantibodies attacking self-DNA, RNA, nuclear antigens and other 
cellular components, resulting in inflammation and organ damage such as renal failure. 
The causes of SLE are not well understood, but genetic susceptibility, viral infection, 
hormonal fluctuation, pregnancy and environmental exposure such as ultraviolet 
radiation and toxic chemicals are believed to instigate the disease. SLE is most 
commonly found in female between 20 and 45. Severe SLE can cause end-stage renal 
failure and heart disease, resulting in high mortality rate. The immunopathogenesis of 
the disease is not fully elucidated. 
The objective of this research was to explore the immunopathological 
mechanism of SLE by studying B cell chemokines CXCL13; dipeptidyl peptidase IV 
containing co-stimulatory molecule CD26; IL-17 releasing T helper lymphocytes 
(Thl7); intracellular signaling pathway of IL-18 activated lymphocytes and 
monocytes and toll-like receptors (TLRs) in patients with SLE. 
SLE patients were recruited from the Rheumatology Out-patient Clinic from the 
Prince of Wales Hospital, Hong Kong. Sex- and age-matched healthy volunteers were 
recruited as controls. Twelve nil of EDTA peripheral blood was collected from 
patients and control subjects. Plasma and peripheral blood mononuclear cells (PBMCs) 
were purified from the blood samples for the following studies. 
For the study of B cell chemokine CXCL13, we measured the expression of 
CXCL13 and soluble TNF receptorl (sTNFRl) in the peripheral blood of SLE 
patients and control subjects by Enzyme-Linked Immunosorbent Assay (ELISA). Our 
results demonstrated that plasma CXCL13 and sTNFRl concentrations were 
significantly higher in SLE patients than in control subjects (p < 0.001), and increase 
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in CXCL13 concentration was positively correlated with SLEDAI score in SLE 
patients (r = 0.399, p = 0.032). 
For the study of CD26, plasma concentration of soluble CD26 (sCD26) and cell 
surface expression of CD26 on monocytes, invariant natural killer T (NKT), Th, Tc 
plus Ts and B lymphocytes were analyzed using ELISA and flow cytometry, 
respectively. Although there was no significant difference between plasma 
concentration of sCD26 in SLE patients and control subjects (p > 0.05), there was 
significant down-regulation in cell number of iNKT lymphocytes and cell surface 
expression of CD26 on Th and iNKT lymphocyte of SLE patients as compared with 
control subjects (all p < 0.05). 
To elucidate the immunopathological roles of Thl7 lymphocytes in SLE, we 
measured the number of circulating Thl7 lymphocytes in the PBMC of SLE patients 
and control subjects by Enzyme-Linked Immunosorbent Spot (ELISPOT). In addition, 
we have investigated the immune response of the activated PBMC by evaluating their 
ex vivo production of IL-17 upon costimulation in the presence of IL-23, anti-CD3 
and anti-CD28 antibodies. The number of circulating Thl7 lymphocytes was found to 
be significantly higher in SLE patients than control subjects (p < 0.05), and the 
expression of IL-17 was also elevated upon stimulation of IL-23, anti-CD3 and 
anti-CD28 (p < 0.05). 
For the study of intracellular signaling pathway, the expression of 
phosphorylated mitogen-activated protein kinases (MAPKs) such as phospho-p38 
MAPK, phospho-extracellular signal-regulated kinase (phospho-ERK) and 
phospho-cJun NH2-termiiial kinase (phospho-JNK) in resting (basal expression) or 
inflammatory cytokine IL-18 activated monocytes, Th, Tc plus Ts and B lymphocytes 
were subjected to flow cytometric analysis. Our results demonstrated that the 
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expressions of phospho-p38 MAPK were significantly increased in resting and IL-18 
activated Th and Tc plus Ts and B lymphocytes of SLE patients than control subjects 
(all p < 0.05). We have also found that the expressions of phospho-JNK was 
significantly elevated in Tc plus Ts and B lymphocytes of SLE patients upon ex vivo 
activation by IL-18 (all p < 0.05). In addition, the expression of phospho-JNK in 
IL-18 activated Tc plus Ts lymphocytes, and the relative percentage increase of 
phospho-JNK expression in IL-18 activated B lymphocytes were positively correlated 
with SLEDAI (r = 0.46, p = 0.044; r = 0.41, p = 0.041). However, no significant 
difference was observed for the expressions of phospho-ERK in resting or IL-18 
activation monocytes, T and B lymphocytes among SLE patients and control subjects 
(all p > 0.05). 
For the study of TLRs, the differential expressions of TLRl to 9 in monocytes, 
Th, Tc plus Ts and B lymphocytes were assessed by flow cytometry. We have reported 
that the intracellular TLRs (TLR 3，8，9) and extracellular TLRs (TLR 1，2, 4，5, 6) 
were elevated in monocytes, Th, Tc plus Ts and B lymphocytes of SLE patients than 
control subjects (p < 0.001). Moreover, the expression of TLR4 on Th and Tc plus Ts 
lymphocytes, together with the expression of TLR6 on B lymphocytes, were 
positively correlated with SLEDAI (TLR4 in Th, Tc plus Ts lymphocytes: r = 0.536, p 
=0.04; r = 0.713，p = 0.003; TLR6 in B lymphocytes: r = 0.572, p = 0.026). 
Based on our studies on CXCL13, CD26, Thl7 lymphocytes, intracellular 
signaling molecules and TLRs in SLE patients, we have achieved better 
understandings of immunopathological mechanism of SLE, which may shed light in 
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示’血漿 C X C L 1 3 和 s T N F R l 濃度在 S L E 患者中均顯著高於控制組（ p < 
0.001) ’而C X C L 1 3濃度與 S L E疾病活動指數呈正相關（ r = 0.399, p = 0 . 0 3 2 ) � 
在CD26的硏究中，我們使用酶聯免疫吸附試驗及流式細胞技術量度可溶 
性C D 2 6 ( s C D 2 6 )在血漿中的濃度以及C D 2 6在細胞表面上的表達’當中包括輔 
助性T ( T h )淋巴細胞，恒定性自然殺手T ( i N K T )淋巴細胞，細胞毒性T ( T c ) 淋 
巴細胞加上抑制性T ( T s )淋巴細胞，單核細胞及B淋巴細胞。雖然血槳中 
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於對照組（P < 0.05)，而且被白介素-23 ’抗CD3抗體和抗CD28抗體共刺激的 






細胞’ Tc加Ts淋巴細胞以及B淋巴細胞內的磷酸化p38 MAPK表達均顯著高於 
對照組（P < 0.05)�我們還發現，SLE患者中的Tc加Ts淋巴細胞以及B淋巴細 
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細胞中擁酸化JNK的相對增加的百分比和SLEDAI呈正相關（r = 0.46, p = 0.044 ； 








的Tol l樣受體（Tol l樣受體1號，2號，4號，5號和6號）在SLE患者的單核 
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Th淋巴細胞爲：r = 0.536，p = 0 . 0 4 ； Tol l樣受體4號於Tc加Ts淋巴細胞爲： r = 
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Chapter 1 General Introduction 
Chapter 1 
General Introduction 
1.1 Characteristics and Prevalence of SLE 
Characteristics of SLE 
Systemic Lupus Erythematosus (SLE) is an autoimmune disease often associated with 
severe morbidity. The term "Lupus", in Latin meaning "wolf , was first used by the 
thirteenth century physician Rogerius for describing the erosive facial lesions of SLE 
patients that resemble a wolfs bite [Boltzer et al., 1983]. 
Production of autoantibodies is a prominent feature of SLE [Kotzin, 1996]. Normally, 
the immune system produces antibodies to protect our bodies from viruses, bacteria and 
other foreign materials. In SLE, however, patients suffer from severe breakdown of 
self-tolerance, which results in the production of pathogenic autoantibodies against self-
antigens including DNA, RNA and nucleic acid components. The deposition of immune 
complex resulting from antigen-antibody interaction can cause inflammation in various parts 
of the body, including the skin, joints, blood, kidneys and brain, causing in severe morbidity 
[Kotzin, 1996]. 
Prevalence of SLE 
The worldwide prevalence rates of SLE are variable, from 0.012% (12/100,000) in 
Britain to 0.039% (39/100,000) in Sweden. In New Zealand, the prevalence rate is 0.05% 
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(50/100,000) among Polynesians, compared with only 0.015% (15/100,000) in the white 
population. In addition, African Americans have a higher prevalence than Caucasians (2.5- to 
6-fold higher relative risk) [Hart et al., 1983]. In China, the prevalence rates of SLE were 
0.07% (70/100,000), 0.03% (31/100,000) and 0.05% (47/100,000) in Shanghai, Guangzhou 
and Shandong, respectively [Zeng et al., 2008]. 
Sex and A2e 
Gender and age also contribute to the onset of SLE. The disease predominantly affects 
women of childbearing age, with a female to male ratio greater than 8:1 [Kotzin, 1996]. A 
local survey of 640 SLE patients from Queen Mary and Tuen Mun Hospitals revealed that 
the most common commonest age of the onset of the disease is between 20 and 45 years old 
[Mok, 2002]. 
1.2 Diagnosis of SLE 
The clinical manifestations of SLE are extremely diverse and new symptoms may 
develop throughout the disease period. To assist physicians in diagnosis, the American 
College of Rheumatology (ACR) in 1982 issued a list of 11 symptoms that help distinguish 
SLE from other diseases. The ACR criteria can be classified into cutaneous, systemic and 
laboratory aspects based on their characteristics, and patients having four or more of these 
symptoms are classified of SLE (Table 1.1) [Tan et al.’ 1982]. Among various symptoms, 
antinuclear antibody (ANA) is most frequently found in the patients and is thus a very 
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sensitive marker for the disease. However, it is non-specific for SLE and may be found in the 
normal population and in many other rheumatic disorders. Therefore, ANA is regarded as a 
screening test before further investigations are arranged. Antibodies to double-stranded DNA 
(anti-dsDNA) and Smith antigen (anti-Sm) are specific marker for SLE, though they are less 
sensitive than ANA [Paz et aL, 2007]. 
Table 1.1 American College of Rheumatology Criteria for the Classification of SLE 
(modified from Tan et al.) 
Cutaneous criteria 
1. Butterfly rash (lupus rash over the cheeks and nose) 
2. Discoid rash (a thick, dislike rash that scars, usually on sun exposed area) 
3. Sun sensitivity (rash after being exposed to UV A and B light) 
4. Oral ulcerations (recurrent sores in mouth or nose) 
Systemic criteria 
5. Arthritis (inflammation of two peripheral joints with tenderness, swelling, or fluid) 
6. Serositis (inflammation of the lining of the lung, or the heart) 
7. Kidney disorder (proteinuria or abnormal sediment in urine) 
8. Neurological disorder (seizures or psychosis) 
Laboratory criteria 
9. Blood abnormalities (hemolytic anemia, low white blood cells counts, low platelet counts) 
10.Immunological disorder (antiphospholipid antibodies, anti-DNA, positive anti-Sm) 
11. Positive Antinuclear antibody blood test 
3 
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1.3 Assessment of Disease Severity 
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), first proposed by a 
group of physicians and statisticians in the University of Toronto in 1992, is an important 
index for doctors to assess the SLE disease severity [Bombardier et al., 1992]. As a global 
index, it includes 24 clinical and laboratory variables weighted by the type of manifestation 
[See appendix]. The disease activity may reach 105 theoretically, but it is rare to find a 
patient with a score over 20. 
1.4 Causes of SLE 
Causes of SLE are complicated and not clearly understood. Familial aggregation of SLE 
has been observed in twin studies and genetic models, suggesting that the disease may be 
genetically linked [Deapen et al” 1992]. However, SLE manifestation can be modified by 
environmental and hormonal factors experienced by individual, implying that the disease 
causes can be multi-factorial [Block et al., 1975]. 
1.4.1 Genetic Factors 
In twin studies, an increased concordance rate of SLE is observed among moiiozygous 
twins (24% to 69%), which is about 10 times higher than the dizygotic one (2% to 9%). This 
supports the importance of genetic influence on SLE [Deapen et al., 1992]. Since the early 
1970s, scientists have strived to search for SLE specific genes by association and linkage 
studies. Instead of identifying a single gene mutation, a number of SLE susceptible genes 
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were found to contribute additively for the development of SLE: 
The HLA Res ion 
The human major histocompatibility (MHC) genomic region located at chromosome 6 
(6p21) encodes the human leukocyte antigen (HLA) gene and many genes that are essential 
for regulating the immune system. The highly polymorphic MHC class II genes HLA-DR2 
and HLA-DR3 have been associated with SLE with a 2- to 3- fold increased risk in 
Caucasian populations [Grennan et al,, 1997]. Since antigen recognition by T lymphocytes is 
dependent on the presence of specific MHC molecules, HLA class II alleles may show strong 
association with the autoantibody profiles. 
Fey Receptors 
The Fc-gamma receptor (FcyR) genes also contribute to SLE susceptibility. Single 
nucleotide polymorphisms (SNP) of FcyRIIA, FcyRIIIA, FcyRIIB and FcyRIIIB, a cluster of 
four genes located at chromosome 1 (lq23), was found to be associated with SLE by altering 
the functions of phagocytic cells via altered binding affinity to respective subclass of IgG. 
[Nath et al” 2004]. 
Complement Components 
Complement gene products play vital roles in prevention of autoimmunity by rapid 
clearance of immune complex and apoptotic debris. Deficiency of complement components 
Ciq, C4 and C2 can significantly increase the risk of developing SLE. In addition, deficiency 
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of Clr/s, C5 and Cg have also reported to induce SLE-like syndromes [Nath et al., 2004]. 
Others 
SNP in several other genes were also associated with SLE. Among them are protein 
tyrosine phosphatase N22 (PTPN22), C-reactive protein (CRP), mannose-binding lectin 
(MBL), cytokine genes such as tumor necrosis factor (TNF), and interferon-alpha (IFN-a). 
Deficiency of these genes may result in disruption of the innate or adaptive immune response, 
which may lead to SLE manifestation [Nath et al, 2004; Croker, 2005]. 
1.4.2 Hormonal Factors 
Hormones can modulate the immune system by altering the expression of a variety of 
genes that control the proliferation, differentiation, and apoptosis of immune cells. It also 
regulates the production of cytokines and cell adhesion molecules. Aberrant hormone 
expressions, therefore, may disrupt the immune balance and instigate autoimmunity. 
Given that women are more susceptible to SLE than men are, the role of sex hormones 
in SLE pathogenesis has drawn serious attention. In general, estrogens are frequently 
reported to promote and activate the immune response whereas androgen and progesterone 
are considered to be suppressive [Butterworth, 1967]. Estrogen, which is well known for its 
close association with SLE, can enhance proliferation of T lymphocytes and macrophages 
and affects apoptosis of autoreactive B lymphocytes [Gourdy et al., 2005]. Two markers of T 
lymphocyte activation, calcineurin and CD 154 were also found to be upregulated by 
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estrogen in SLE but not in normal T lymphocytes [Rider, 1998; Rider, 2001]. 
1.4.3 Environmental Factors 
The lack of 100% concordance rate of SLE in monozygous twins imply that 
environmental factors are important for triggering the disease onset. Some of these factors 
include drugs, UV radiation, infectious agents, toxic chemicals and lifestyle. 
Druss 
A variety of drugs have been reported to instigate the onset of SLE, with procainamide 
and hydralazine being the best-studied drugs that can modify epigenetic mechanisms of T 
lymphocytes, resulted in abnormal expression of genes implicated in the pathogenesis of 
SLE [Yung, 1994]. 
UV Radiation 
UV radiation is the most well known environmental trigger of SLE. Although the exact 
mechanism is not clearly understood, it is commonly believed that UV radiation might alter 
DNA methylation and increase apoptosis, resulted in aberrant immune response [Fruchter, 
2005]. 
Infections 
The association between SLE and infectious agents has been extensively reported by 
investigators, with Epstein-Barr Virus (EBV) being the most studied candidate. EBV 
contributes to SLE pathogenesis by the production of viral proteins mimicking the host 
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molecules, which results in stimulation of autoantibodies [Kang et al., 2004]. In addition, it 
can alter the immune response by activation and immortalization of B lymphocytes 
[Zandman, 2005]. 
Toxic chemicals 
A variety of chemical factors and heavy metals has been reported to associate with SLE, 
examples include crystalline silica, mercury, pesticides and hair dyes [Hess, 2002]. 
1.5 Drug Treatment of SLE 
Treatments of SLE focus on suppressing the active phase of the disease without causing 
long-term damage. Varieties of non-steroid drugs have been used empirically. These include 
the non-steroid anti-inflammatory drugs (NSAIDs)，anti-malarials and retinoids (eg: 
thalidomide) [Harris et al., 2005]. 
Steroids are among the most effective and universally used anti-inflammatory drugs for 
treating SLE. Prednisone is a kind of synthetic corticosteroid that is most commonly used in 
the treatment of SLE. Although these drugs can cause undesirable side effects such as weight 
gain, insomnia and immunosuppression, their uses can substantially reduce the symptoms 
associated with inflammation, such as swelling, warmth, tenderness and pain [Harris et al., 
2005]. 
Cytotoxic agents such as azathioprine, cyclophosphamide and methotrexate are reserved 
for moderate to severe disease. These agents are anti-metabolites that are able to interrupt 
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nucleic acid and protein synthesis, causing significant side effects [Harris et al., 2005]. 
1.6 Immunological Dysregulation in SLE 
1.6.1 Types and Properties of Lymphocytes 
Lymphocytes are small leukocytes (7 to 8 fim) having a characteristic large nucleus and 
contribute 20-40% of all leukocytes in blood. The three major types of lymphocyte are B 
lymphocytes, T lymphocytes and natural killer (NK) lymphocytes. B lymphocytes, derived 
from bone marrow, are involved in humoral immune response. Their major function is to 
secrete large amount of antibodies when exposed to foreign antigens, which can assist the 
phagocytes in the destruction of pathogens. T lymphocytes, derived from thymus, are key 
mediator in cell-mediated immunity. They express T cell receptors (TCRs) which recognize 
specific antigenic peptides presented by MHC Class 1 molecules on the surface of antigen 
presenting cells (APCs). They can be categorized into several subpopulations such as T 
helper (Th) lymphocytes, cytotoxic T (Tc) lymphocytes, suppressor T (Ts) lymphocytes, 
memory T lymphocytes, regulatory (Treg) lymphocytes and natural killer T (NKT) 
lymphocytes [Janeway et ai, 2001]. The different subsets of T lymphocyte serve distinct 
function respectively. 
Th lymphocytes, expressing CD4 glycoprotein on their surface, act as the "middlemen" 
of the adaptive immune system. Once activated, they divide rapidly and secrete various 
cytokines that regulate the immune response. They have been conventionally classified into 
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Thl and Th2 lymphocytes. Thl lymphocytes are involved in cell-mediated immunity by 
maximizing the killing efficacy of macrophage and enhancing the proliferation of Tc 
lymphocyte. Th2 lymphocytes mainly take part in the humoral immunity by stimulating B 
lymphocytes proliferation and increasing antibodies production. Recently, a novel subset of 
T lymphocytes which develop and behave in a distinct way from Thl or Th2 lymphocytes 
has been identified. It mainly produces proinflammatory cytokines such as IL-17 A, IL-17F, 
IL-21 and IL-22 and is designated as Thl7 lymphocyte. 
Tc lymphocytes, a sub-population of CD8+ T lymphocytes, play a key role in 
cell-mediated immunity. They are capable of inducing virus infected or tumor cell death. 
They are also involved in transplant rejection. [Janeway et al., 2001]. 
Memory T lymphocytes are a subset of antigen-specific T lymphocytes that can 
recognize foreign invaders such as previously encountered bacteria or viruses. Upon 
re-exposure to their cognate antigen, they can quickly expand to large numbers of effector T 
lymphocytes to mount a faster and stronger immune response, thus providing the immune 
system with "memory" against past infections [Janeway et al., 2001]. 
Treg and Ts lymphocytes are key modulators of immunological tolerance. Ts 
lymphocytes are CD8+CD28- phenotype of T cell populations, which can inhibit Th 
lymphocytes activity either by a contact-dependent mechanism or by secreting suppressive 
cytokines such as TGF-P and IL-10. Two major classes of Treg lymphocytes have been 
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characterized. The first subset is the naturally occurring Treg lymphocytes 
(CD4+CD25+FoxP3+) which developed during the normal process of T-cell maturation in 
the thymus. The second subset is the adaptive Treg cells that develop as a consequence of 
activation of T lymphocytes under particular conditions of co-stimulation. Different features 
of natural and adaptive Treg cells were summarized in Table 1.2 [Bluestone et aL, 2003]. 
Table 1.2: Comparison between Natural and Adaptive Regulatory T lymphocytes 
Feature Natural Treg lymphocytes Adaptive Treg lymphocytes 
Site of induction Thymus Periphery 
CD28-CD86 dependent Yes No 
IL-2 dependent Yes Yes 
CD25 expression Yes (high) Variable 
Specificty Self-antigen in thymus Tissue-specific antigens and 
foreign antigen 
Mechanism of T-cell-T-cell/APC contact, T-cell-T-cell/APC contact, 
effector-cell supression cytokine independent cytokine dependent 
NK lymphocytes, expressing the surface markers CD16 and CD56, are important in 
rejecting tumor and virus-infected cells by releasing perforin and granzyme for cell apoptosis 
or necrosis. Natural killer T (NKT) lymphocytes are a specific group of lymphocytes that 
share properties of both T lymphocytes and NK lymphocytes, and constitute 0.1 to 0.5% of 
all peripheral blood T lymphocytes [Kronenberg, 2005]. They can recognize lipids and 
glycolipids present by CD Id molecules, which is a member of the CDl family of 
antigen-presenting molecules, rather than peptide-MHC complexes. Upon activation, NKT 
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lymphocytes are able to produce large quantities of IFN-y, IL-4, and 
granulocyte-macrophage colony-stimulating factor (GMCSF), as well as multiple other 
cytokines and chemokines (such as IL-2 and TNF-a) [Janeway et al, 2001]. 
Lymphocyte Dysresulation and the Pathogenesis of SLE 
Several aspects of abnormal regulation of lymphocytes may contribute to autoimmunity 
in SLE. These include disruption of immune tolerance, abnormal response to autoantigens, 
abnormal display of autoantigens, and pathological alterations in signal transduction across 
the T cell receptors. 
It has been suggested that SLE is a Th2-polarized disease because of the polyclonal 
B-cell activation observed in SLE. [Mohan et al” 1993]. For example, peripheral blood 
mononuclear cell (PBMC) of SLE patients showed up-regulation of Th2 cytokines IL-4 and 
IL-10 [Mosmann et al., 1989]. However, our group has recently demonstrated that 
concentrations of plasma Thl cytokines IL-12, IL-18 are significantly higher in SLE patients 
[Wong et al., 2000]. The increased production of the Thl cytokines should exert a synergistic 
effect ill inflammatory reactions, leading to elevated production of a panel of 
pro-inflammatory cytokines in SLE. Collectively, the activation of both Thl and Th2 
cytokines appears to be important in the pathogenesis of SLE. 
Thl7，a novel Th subset, has also been found important in the development of 
autoimmune diseases by inducing tissue injuries, inflammation and infection [Kikly et al., 
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2006]. It primarily produces two main members of the IL-17 cytokines family, IL-17A and 
IL-17F，which participate in the pro-inflammatory cascade for neutrophils recruitment, 
activation and migration. IL-6 and IL-ip are required for the differentiation of Thl7 
lymphocytes while IL-23 is essential for their survival and proliferation. Studies on the Thl7 
subset and its relevant issues offered potential therapeutic targets for patients with 
autoimmune diseases, which may have significant impacts in the prevention and treatment of 
immunity-related diseases. [Kikly et al., 2006] 
NKT lymphocytes are also essential for several aspects of immunity. Most of them 
express the invariant Va24/Vpi l T cell receptors, which are referred to as invariant NKT 
(iNKT) lymphocytes. They are conserved between humans and mice and are implicated in 
many immunological processes. The clinical potential of NKT lymphocytes lies in the rapid 
release of cytokines (such as IL-2, IFN-y, TNF-a, and IL-4) that promote or suppress 
different immune responses. Accumulated evidences have confirmed that the circulating 
number and function of NKT lymphocytes are reduced in patients with various autoimmune 
diseases. Examples include type 1 diabetes [Kukreja et al., 2002]，systemic sclerosis, 
rheumatoid arthritis [Kojo et al” 2001], multiple sclerosis [Gausling et al； 2001], and SLE 
[Kojo et al., 2001], suggesting that NKT lymphocytes play suppressive role in autoimmune 
diseases. 
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1.6.2 Cytokines and Chemokines 
Cytokines are a group of small peptides or glycoproteins produced by a wide variety of 
cells. They have molecular weights between 8 to 30 kDa and exhibit a diverse range of 
actions such as inducing activation, growth, differentiation, cytolysis, apoptosis and 
chemotaxis of cells. More importantly, they are key mediators of immunity and inflammation, 
and are involved in the pathophysiology of a wide range of diseases [Janeway et al； 2001]. 
Nomenclature of cytokines is mainly based on their function, cell of secretion, or target 
of cell. The term interleukins refer to cytokines whose targets are leukocytes, and most of 
them are produced by Th lymphocytes. The term chemokines refer to a group of smaller 
cytokines (mass between 8 to 12 kDa) with chemotactic properties [Janeway et al., 2001]. 
They can interact with their corresponding receptors to regulate leukocyte trafficking, 
stimulate leukocyte degraniilation or promote angiogenesis. Some of the functions and 
sources of the major cytokines and chemokines that have been investigated in our project are 
summarized in table 1.2 and table 1.3 respectively. 
Cytokine and Chemokine Expressions in SLE 
Many reports have demonstrated that both Thl and Th2 cytokines may play crucial 
roles in the pathogenesis of SLE. For example, elevated expressions of Th2 cytokine IL-4 
and IL-10 were found in SLE patients' PBMCs [Mosmann et al., 1989]. Moreover, Thl 
cytokine including IFN-y, IL-12 and IL-18 were significantly elevated in SLE patients 
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[Tokano et al., 1999; Wong et al.’ 2000]. It has been reported that IL-12 along with IL-18 
could synergistically induce the expression of inflammatory mediators by T lymphocytes, 
causing severe inflammatory disorders in autoimmune diseases such as rheumatoid arthritis 
[Fehniger et al, 1999]. Our previous cross sectional studies have also shown the level of 
IL-18 in plasma was elevated in SLE patients and correlated with SLEDAI [Wong et al., 
2000; Wong et al., 2002]. We reported that deregulation of Thl-related chemokine CXCLIO 
was positively correlated with IL-18 and SLEDAI, which demonstrates the involvement of 
Thl lymphocyte in the pathogenesis of SLE. [Lit et al., 2006] 
Apart from Thl and Th2 lymphocytes, Thl7 lymphocytes also play important role in 
the pathogenesis of SLE. It mainly produces pleiotropic proinflammaotry cytokine IL-17A 
and IL-17F, which can enhance T lymphocytes priming and stimulate epithelial, endothelial 
and fibroblastic cells to produce multiple proinflammatory mediators including IL-ip, IL-6 
and TNF-a. IL-23, a novel heterodimeric cytokine shares structural similarity with IL-12, is 
required for the expansion of Thl7 lymphocytes [Kikly et al., 2006]. However, the 
involvement of IL-23 in the IL-23/ IL-17 auto-inflammatory axis of SLE has not been fully 
elucidated. 
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Table 1.3 Major functions and sources of cytokines used in this project 
Name Main functions Main sources 
TNF-a Activates macrophages and phagocytosis, attract Leukocytes, inflammed 
neutrophils tissues 
IL-ip Up-regulate the expression of adhesion molecules, Monocytes, macrophages, 
regulates hematopoiesis dendritic cells 
IL-6 Regulates B and T lymphocytes growth and Activated Th2 cells, 
differentiation; activates natural killer (NK) cells monocytes 
IL-10 Inhibits macrophage and T lymphocytes mediated Activated Th2 cells, 
immune inflammation monocytes 
IL-12 Regulates T lymphocytes growth and B lymphocytes, 
differentiation; activates NK cells macrophages 
IL-18 Induces TNF-a and Thl cytokine production, Activated macrophages, 
regulates T lymphocytes growth and differentiation dendritic cells 
IL-17 A Induces the expression of proinflammatory Activated Th 17 
cytokines, chemokines, prostaglandins (PGE) and lymphocytes 
matrix metalloproteinases (MMP) 
IL-23 Induce expression of MMP, increases angiogeiiesis Activated macrophages 
and reduces CD8+ T-cell infiltration, stimulates the 
differentiate of naive CD4+ T cells to Thl 7 cells 
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Table 1.4 Major functions and sources of chemokines studied in this project 
Systemic Name / Main functions Main Sources 
Common Name 
CCL2/ MCP-1 Attracts monocytes, Th2 Monocytes, epithelial and 
lymphocytes, basophils and endothelial cells 
eosinophils 
CCL5 / RANTES Attracts T lymphocytes, Activated T lymphocytes 
basophils and eosinophils; 
activates NK cells 
CXCLl / GRO-a Attracts neutrophils; stimulate Macrophages, neutrophils 
melanoma growth and epithelial cells 
CXCL9 / MIG Attracts Till lymphocytes IFN-y activated macrophages 
CXCL lO/IP-10 Attracts Th 1 lymphocytes, TNF-a or IFN-y activated 
neutrophils and monocytes monocytes and neutrophils 
1.6.3 Toll-like Receptors 
Types and Properties 
Toll-like receptors (TLRs) owe their name to a closely related receptor called Toll, 
which was first identified in Drosophila in 1988 during a screen for embryonic polarity genes 
[Hashimoto et al.’ 1988]. TLRs are a group of pattern recognition receptor (PRR) that can 
recognize structural conserved pathogen-associated molecular patterns (PAMPs) broadly 
shared by pathogens but discernible from host molecules. They form a receptor super-family 
with the IL-1 receptors that all have in common a TIR (Toll-IL-1 receptor) domain [Takeda 
et a/., 2003]. 
Whereas the TLR expression is predominant in antigen presentation cells such as 
macrophages, neutrophils, and dendritic cells, they are not restricted to these cell types. 
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Ongoing research reported that TLR expression is detectable in a wide range of tissues 
including adrenal gland, liver, lung, spinal cord, spleen, testis, thymus and trachea, 
suggesting that TLRs are expressed in the majority of cells in the body [Takeda et al” 2003]. 
The completion of the human genome project led to the identification of more putative 
TLRs in the genome, and at least 11 of them have been identified in humans and 13 in mice 
[Takeda et al., 2003]. These TLRs are distinguishable from each other in terms of ligand 
specificities, expression patterns, and target genes they induce. The ligands and signaling 
pathways of TLRl to TLR9 are summarized in Table 1.4. 
TLRs Sisnalins 
TLRs are considered one of the most ancient, conserved components of the innate 
immune system. Upon binding with their specific PAMPs, they change their intracellular 
domain, resulted in the initiation of signaling events such as the nuclear factor-kappa B 
(NF-kB), mitogen activated protein kinases p38 (p38 MAPKs), Jun-N-terminal kinase (JNK), 
and the interferon pathway. A number of adaptor molecules are involved in the TLR signal 
transduction pathway, these include the myeloid differentiation primary response gene 88 
(MyD88), TIR domain containing adaptor protein (TIRAP), TIR domain-containing adapter 
inducing interferon (TRIP) and TRIF-related adaptor molecule (TRAM). The activation of 
these signaling pathways results in translocation of transcription factors, cytokine 
modulation, and IFN stimulated gene regulation leading to inflammatory responses 
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[Yamamoto et al” 2003]. 
TLR Expressions in the Pathogenesis of SLE 
Accumulating evidence have indicated that TLR stimulation may potentially contribute 
to autoimmune responses. TLR3, TLR8 and TLR9 are endosomal TLRs that recognize 
double-stranded RNA (dsRNA), single-stranded RNA (ssRNA, TLR7 in mice) and 
unmethylated CpG DNA respectively [Takeda et aL, 2003]. Christensen et al. reported that 
lupus-prone mice deficient in TLR7 failed to generate antibodies against RNA-containing 
antigens such as Smith (Sm), resulted in decreased lymphocyte activation and serum IgG. In 
contrast, the absence of TLR9 will cause activation of lymphocytes and plasmacytoid 
dendritic cells (pDCs), hence increasing serum IgG and IFN-a. These findings revealed the 
opposite roles of TLR7 and TLR9 in SLE [Christensen et al., 2006]. In another study, 
patients with active SLE have higher proportion of TLR9 in peripheral blood memory B 
lymphocytes and plasma B lymphocytes, suggesting that endogenous nucleic acids released 
during cell apoptosis may stimulate B lymphocytes via TLR9 and contribute to SLE 
pathogenesis [Papadimitraki et al, 2006]. 
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Table 1.5 Ligands and signaling pathways of TLRs in human 
TLR Host defense Natural ligands Ligands used in Signaling 
this project pathways 
TLR 1 Heterodimer with TLR2 
TLR2 Gram positive PGN, lipoproteins, PGN MyD88, TIRAP 
bacteria, yeast, zymosan, 
mycobacteria, glycolipids 
spirochetes 
TLRS Virus dsRNA Poly IC TRIP 
TLR4 Gram negative LPS, LTA LPS MyD88, TIRAP, 
bacteria TRIP, TRAM 
TLRS Flagellated Flagellin Flagellin MyD88 
bacteria 
TLR6 Heterodimer with TLR2 
TLR7 Vims ssRNA in mice R837 MyD88 
TLRS Virus ssRNA in human ssRNA ？ 
TLR9 Bacteria and virus CpG motifs in DNA CpG DNA DyD88 
TLR 10 ？ ? ？ ? 
TLR 11 Uropathogenic ？ ？ MyD88 
bacteria 
Abbreviation 
PGN : peptidoglycan 
Poly IC : polyinosinic-polycytidylic 
LPS : lipopolysaccharides 
LTA: lipoteichoic acid 
R837 : l-(2-methyl propyl)-lH-imidazo[4,5-c]quinolin 4-amine 
CpG : cytosine-phosphate-guanine 
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1.6.4 Intracellular Signal Transduction Pathways 
Types and Properties 
Signal transduction refers to an ordered biochemical process by which a signal or 
stimulus is transferred within a single cell. The signal cascade beginning with binding of 
extracellular signaling molecules (or ligands) to cell-surface receptors, triggering an initial 
stimulus that is propagated into the cytoplasm. Example of the stimulus include: hormones, 
growth factors, extracellular matrix components, cytokines, chemokines, neurotransmitters 
and neurotrophins. Upon binding with these proteins, the intracellular part of the receptor 
induces conformational changes, stimulating enzymatic activity within the receptor or 
exposing a binding site for other signaling proteins within the cell. The process can last for 
about milliseconds in the case of ion flux, minutes for protein- and lipid-mediated kinase 
cascade, or hours and even days for gene expression. 
Among all signal transduction pathways that have been identified nowadays, 
mitogen-activated protein kinase (MAPK) pathways are the most well-known and 
established. They consist of three major pathways: p38 MAPK, c-Jun NH2-temiinal kinase 
(JNK) and extracellular-regulated protein kinase (ERK) cascades. Their mechanisms are 
illustrated in Figure 1.1. 
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Figure 1.1 MAPK signal pathways (courtesy from Dr. Phyllis Cheung and Miss Amy 
Ho). Three major cascades of MAPK: p38 MAPK, ERK and JNK were illustrated in Figure 
1.1. Upon activation, they undergo phosphorylation and subsequently activate the 
downstream transcription factors such as ATF-2, c-Jun and c-Fos for the production of 
cytokines and regulation of cellular activities. 
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The p38 MAPK is a stress-activated protein kinase and can be activated by osmotic 
stress, UV radiation, ionizing radiation, bacterial cell wall product (e.g.: lipopolysaccharide) 
and various proinflammatory cytokines [Kyriakis et al., 2001]. The main function of p38 
MAPK is to regulate cellular degranulation, chemotaxis and expression of adhesion 
molecules during inflammation. It can also regulate cell cycle progression, differentiation 
and apoptosis [Aouadi et al., 2006]. Upon activation, p38 MAPK is subjected to 
phosphorylation, which can subsequently activate a variety of downstream transcription 
factor. 
The ERK pathway mainly regulates cell proliferation, transformation and differentiation 
after activated by growth factor such as IL-5 [de Groot et al., 1998]. During inflammation, 
ERK activation can promote CXCL8 production from neutrophils [Jo et al., 2004]. Inhibition 
of ERK pathway can also repress lung inflammation via suppressing the Th2 cytokines 
production [Chialda et al” 2005]. Upon activation, ERK can undergo phosphorylation and 
dimerization, which in turn translocates into nucleus for eliciting biological responses 
through downstream transcription factors [Eblen et al., 2002]. 
JNK is a protein kinase cascade responsible for transduction of cellular stress signals 
and can be potently activated by irradiation, inflammatory cytokines and other environmental 
stresses (e.g.: hyperosmolarity) [Derijard et al., 1994]. JNK enhances the transcriptional 
activity of activating protein 1 (AP-1) by phosphorylation [Hibi et al., 1993]. Binding sites 
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for AP-1 exist in the promoter regions of several cytokine genes including those encoding 
CXCL8 and CCL5 [Mukaida et al., 1989; Nelson et al” 1993]. 
Intracellular Sisnalins Pathways in SLE 
It is well established that the p38 and JNK pathways are activated by inflammatory 
cytokines and cellular stressors such as osmotic stock and UV radiation. They are generally 
recognized as the main driver behind the pathophysiology of inflammation-mediated 
diseases, while proliferative and neoplastic responses are the domain of the ERK pathway. 
p38 MAPK and ERK are also found to play important roles in inflammation by inducing the 
production of inflammatory cytokine IL-6 and chemokine CXCL8，CCL2, CCL5, CXCL9 
and CXCLIO [Wong et al., 2005]. Increasing evidences have shown that abnormality in 
intracellular signaling molecules such as nuclear factor-kappa B, protein tyrosine kinase and 
protein kinase C are associated with T lymphocyte dysregulations in SLE [Blasini et al., 
1998; Wong et al., 1999; Tada et al., 1991]. However, the effect of intracellular activation of 
ERK, JNK and p38 MAPK on the induction of abnormality of T lymphocytes, B 
lymphocytes and monocytes, and their relationship with SLE pathogenesis has not been fully 
elucidated. 
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1.7 Objectives of Our Study 
The pathogenesis of SLE is characterized by the deposition of immune complexes 
resulting in systemic inflammation, as exemplified by the elevated expression of 
inflammatory cytokines and chemokines in plasma of SLE patients [Lit et al., 2006; Wong et 
al., 2000]. However, the pathogenesis of the disease has not been fully elucidated. The 
objective of this MPhil project, therefore, is to address the pathogenesis of SLE in the 
following studies: 
The first study was to investigate the role of B cell chemokine CXCLl 3 and its 
correlation with proinflammatory cytokine, TNF-a in SLE patients. Plasma concentrations of 
CXCL13, soluble TNF Receptor R1 (sTNFRl) and gene expression of TNF-a were 
measured by ELISA (R&D Systems) and real-time PGR (Applied Biosystems) respectively, 
and their correlation with SLE disease activity was calculated using statistical software 
(SPSS). 
The second study was to explore the role of CD26, which is a co-stimulatory molecule 
as well as dipeptidyl peptidase IV (DPPIV), in the pathogenesis of SLE. Cell surface 
expression of CD26 in B lymphocytes, T lymphocytes, monocytes and iNKT lymphocytes 
was assayed using cell surface staining technique and analyzed by flow cytometry. 
The third study was to elucidate the intracellular signaling pathways in SLE. 
Intracellular expression of phosphorylated MAPK signaling molecules (namely, 
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phospho-p38 MAPK, phospho-ERK and phospho-JNK) in B lymphocytes, T lymphocytes 
丁 N/! 
and monocytes was measured by BD PhosFlow activation state analysis (BD Bioscienses) 
using flow cytometry. 
The fourth study was to examine the pathogenic role of IL-23/IL-17 autoinflammatory 
axis in SLE. The expression of IL-17 in PBMC upon co-stimulation by CD3/CD28 and 
IL-23 was measured by ELISA (R&D Systems). Moreover, the number of Thl 7 lymphocytes 
in PBMC upon PMA and ionomycin activation was detected using ELISPOT (eBioscience). 
Finally, we have investigated the activation of B lymphocyte, T lymphocytes and 
monocytes by measuring cell surface or intracellular expression of TLR 1 to TLR9 using flow 
cytometry. The cytokine expressions by PBMCs upon TLR ligands activation was evaluated 
by BD'm Cytometric Bead Array (CBA) (BD Pharmingen) using flow cytometry 
(FASCalibur, BD Biosciences). 
In summary, this project has set out to investigate the activation of monocytes, T 
lymphocytes and B lymphocytes in the pathogenesis of SLE by various stimuli and the 
underlying intracellular signaling mechanisms. Further investigation on the expanding 
cytokines and chemokines family on the manifestation of the disease are still on progress. 
We believe that through continuous exploration and investigation, an improved 
understanding of the immunopathology of SLE can be achieved and better approaches for 
potential therapies may be feasible in the near future. 
26 
Chapter 2 Materials and Methods 
Chapter 2 
Materials and Methods 
2.1 Materials 
2.11 SLE Patients and Control Subjects 
The protocol for study of patients and control subjects was approved by the 
Clinical Research Ethics Committee of the Chinese University of Hong Kong - New 
Territories East Cluster Hospitals, and informed consent was obtained from all 
participants according to the Declaration of Helsinki. 
SLE Patients and Control Subjects 
Chinese adult SLE patients aged 21 to 65 were recruited from the Rheumatology 
Outpatient Clinic of the Prince of Wales Hospital, the teaching hospital of the Chinese 
University of Hong Kong. Diagnosis of SLE was established according to the 1982 
revised American Rheumatism Association criteria (ARA) [Tan et al.’ 1982], and 
disease activity was evaluated by the SLE disease activity index (SLEDAI) score 
[Bombardier et al” 1992]. Sex- and age-matched healthy Chinese volunteers were 
recruited as control subjects. 
Twenty mL of venous peripheral ethylenediaminetetraacetic acid (EDTA) blood 
was collected from each patient and control subject. Aliquots of whole blood were 
processed immediately for ex vivo study and peripheral blood mononuclear cell 
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(PBMC) isolation. Plasma samples were preserved at -70°C for subsequent assays. 
2.1.2 Reagents for Cell Culture 
Culture Medium - RPMI 1640 Medium 
RPMI 1640 medium was purchased from Gibco Invitrogen Corporate, CA, USA. 
The medium is in liquid form, and is supplemented with 2 niM L-glutamine and 25 
mM N-2-hydroxyl-ethyl-piperazine-N'-2-ethane -sulfonic acid (HEPES) buffer. 
Serum Supplement to Culture Medium 
Fetal calf serum (FCS) was purchased from Hyclone Co, MA, USA. The medium 
has been tested with low endotoxin (<10 EU/mL) and hemoglobin (<10mg/mL) level. 
Dve Solution - Trypan Blue Solution 
Trypan blue solution was purchased from Sigma Chemical Co., MO, USA. It 
was used at a working concentration of 0.4 % in 0.81 % sodium chloride (NaCl) and 
0.06 % dibasic potassium phosphate (K2HPO4). It was sterile-filtered and used for cell 
counting. 
Phosphate Buffered Saline (PBS) Solution 
Dulbecco's PBS (DPBS) powder packs without calcium and magnesium were 
purchased from Gibco Invitrogen Corp. PBS solution was prepared by dissolving one 
power pack in 1 L of distilled water, which was then sterilized by autoclaving at 
121°C for 30 min. 
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Ficoll-Plaaue™ PLUS solution 
Ficoll-Plaque™ PLUS solution was purchased from GE Healthcare Life Sciences, 
CA, USA. It was used for the isolation of lymphocytes from human peripheral blood. 
Recombinant Human Cytokines 
Recombinant human IL-18 and IL-23 were purchased from R&D Systems Inc., 
MN, USA. They are lyophilized recombinant proteins derived from Escherichia coli. 
They were reconstituted to 20 |j,g/mL in sterile PBS solution and kept as 20 |j,L 
aliquots at -70°C until use. 
TLR Lisands 
Ultra-purified LPS from E. coli K12 strain without any contamination by 
lipoprotein, R837 (Imiquimod, a synthetic antiviral molecule), single- stranded RNA 
(ssRNA) and CpG DNA, for human TLR4, 7, 8 and 9 respectively were purchased 
from InvivoGen Corp, CA, USA. 
Flagellin for human TLR5 was purchased from Calbiochem Corp, CA, USA. 
Double-stranded polyinosinic-polycytidylic acid [poly IC] for human TLR3 was 
purchased from Sigma. Peptidoglycan (PGN) for human TLR2 was purchased from 
Fluka Chemie AG, Geneva, Switzerland. Ligands for TLRl and TLR6 were not 
included because they form heterodimer with TLR2. 
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2.1.3 Reagents for Flow Cytometry 
Fluorescence Activated Cell Sorting (FACS) Stainins Medium 
FACS staining medium was prepared by dissolving 0.05 g of sodium azide 
(NaN3) in 100 mL PBS and supplemented with 2 % FCS. The medium is stored at 
BP FACSFIowTm Sheath Fluid 
BD FACFlowiM Sheath Fluid was purchased from Becton Dickinson (BD) 
Biosciences, NJ, USA. It was a balanced electrolyte solution containing sodium 
chloride (NaCl), potassium chloride (KCl), disodium EDTA, sodium fluoride (NaF) 
and anti-microbial agent. 
BD FACSFlow™ Rinse Solution 
BD F A C S F 1 o w � m Rinse Solution was purchased from BD Biosciences. It was a 
detergent solution for cleaning the flow cytometer. 
CmHBRITE™ Beads (CaliBRITE 3 and APC Beads) 
CaliBRITE Beads were purchased from BD Biosciences. They were used to 
adjust instrument settings, set fluorescence compensation, and check instrument 
sensitivity. 
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Paraformaldehyde for Cell Fixation 
Paraformaldehyde was purchased in power form from Sigma Chemical Co. It 
was dissolved in PBS to obtain a stock concentration of 2.5% and used at working 
concentration of 1 % for cell fixation during intracellular immunofluorescence staining 
ofPBMC. 
Human Serum 
Human serum was obtained from venous blood of Chinese healthy volunteers 
and stored at -20°C. It was used for the blocking procedure in cell surface 
immunofluorescence staining of PBMC. 
Monoclonal Antibodies for Cell Surface Molecules 
The anti-human monoclonal antibodies for cell surface molecules used in this 
project are summarized in Table 2.1. All of them were stored at 4°C. 
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Table 2.1 List of anti-human monoclonal antibodies for cell surface molecules 
Monoclonal antibodies Fluorescence Stock conc. Amount added Supplier 
conjugation per 5 x 10® cells 
CD3, nisIgG, PerCP 12.5 |.ig/mL 4 BD Biosciences 
CD4, msIgG, PE 12.5 }ig/niL 4 BD Biosciences 
CDS, msIgG, PerCP 12.5 |ag/mL 4 BD Biosciences 
CD19, msIgG, APC 12.5 fig/niL 4 BD Biosciences 
CD26, msIgGi Purified 50 itig/niL 4 BD Biosciences 
CD28, msIgGi Purified 50 fig/mL 4 BD Biosciences 
Invariant Va24-JaQ FITC 12.5 ng/niL 4 BD Biosciences 
TCR chain, msIgGi 
Invariant VP11 PE 12.5 f.ig/niL 4 BD Biosciences 
TCR chain, msIgG, 
TLRl , msIgGi Purified 0.5 mg/mL 3 Imgenex 
TLR2, msIgG, FITC 0.5 mg/mL 3 Imgenex 
TLR4，msIgG, FITC 0.5 mg/mL 3 Imgenex 
TLR5，msIgG, FITC 0.5 mg/mL 3 Imgenex 
TLR6, msIgGi Purified 0.5 mg/niL 3 Imgenex 
msIgGi IC Purified 50 [ig/mL 4 BD Biosciences 
msIgG, IC FITC 50 ng/mL 4 BD Biosciences 
Goat anti-mouse IgG, FITC 3 |ig/mL 80 Zymed 
Laboratories 
Abbreviations: 
FITC : Fluorescein isothiocyanate Purified : No conjugation of fluorescence 
PE : Phycoerythrin IC : Isotypic control 
PerCP : Peridinin - Chlorophyll - Protein msIgGi： Mouse IgGi 
APC : Allophycocyanin rlgGi： Rabbit IgGi 
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Monoclonal Antibodies for Intracellular Molecules 
The anti-human monoclonal antibodies for intracelluar molecules used in this 
project are summarized in Table 2.2. All of them were stored at 4°C. 
Table 2.2 List of anti-human monoclonal antibodies for intracellular molecules 
Monoclonal Antibodies Fluorescence Stock conc. Amount added Supplier 
Conjugation per 5 x 10® cells 
TLR3, msIgG, FITC 0.5 mg/mL 3 |_iL Imgenex 
TLR7, rlgGi Purified 0.5 mg/mL 3 |_iL Imgenex 
TLRS, msIgGi FITC 0.5 mg/mL 3 |iL Imgenex 
TLR9, msIgG, FITC 0.5 mg/mL 3 |iL Imgenex 
Mouse IgG] Isotype FITC 0.5 mg/mL 3 |_iL BD Biosciences 
Rabbit IgG! Isotype Purified 0.5 mg/mL 3 |iL BD Biosciences 
Goat anti-rabbit IgG, FITC 3 |iig/niL 80 Zymed 
Laboratories 
2.1.4 Reagents for Phosphorylation State Analysis 
BD™Phosflow phosphorylation state analysis was applied. All reagents and 
buffers were purchased from BD Biosciences and listed below: 
BD Cvtofix Buffer 
It comprised of DPBS at pH 7.4 with 4% paraformaldehyde. It was used to fix 
unstained cells for subsequent immunofluorescent staining of intracellular kinases and 
stored at 4°C. 
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Perm Buffer III 
This was a buffered solution containing 90% methanol and other proprietary 
ingredients and could be stored at room temperature. It was used for permeabilization 
following fixation of cells. 
Stain Buffer 
It was DPBS with 2% heat-inactivated FCS and 0.09% sodium azide at pH 7.4 
and stored at 4°C. It was useful for the dilution and application of fluorescent reagents 
as well as for the suspension, washing and storage of cells destined for flow 
cytometric analysis. 
Monoclonal Antibodies Used in Phosphorvlated State Analysis 
The monoclonal antibodies applied in this analysis are listed in Table 2.3. All of 
them were stored at 4°C. 
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Table 2.3 List of anti-human monoclonal antibodies used for intracellular 
phosphorylated state analysis using flow cytometry 
Monoclonal Antibodies Fluorescence Stock Amount Supplier 
conjugation Cone. added per 5 x 
10® cells (nL) 
Phospho-p38 MAPK, Purified 50 |.ig/mL 8 BD Biosciences 
msIgGi 
Phospho-JNK, Purified 50 ng/mL 8 BD Biosciences 
msIgGi 
Phospho-ERKl/2, Purified 50 |.ig/mL 8 BD Biosciences 
msIgGi 
msIgGi Isotype Purified 50 |ig/niL 8 BD Biosciences 
Goat anti-mouse IgGi FITC 3 |ig/mL 80 Zymed 
Laboratories 
2.1.5 Reagents for Total RNA Extraction 
DNase/ RNase-free DEPC treated distilled water 
Double distilled water was treated with 0,1% diethyl pyrocarbonate (DEPC) 
which was purchased from Sigma-Aldrich. The mixture was shaken thoroughly to 
disperse the DEPC and left standing overnight before being autoclaved at 121°C for 
15 min. 
Oiasen RNeasy Total RNA Extraction Kit 
This kit was purchased from Qiagen GmbH, Hilden, Germany and used to 
extract total RNA from purified PBMC. It consists of four components: (i) lysis buffer 
RLT, with guanidine isothiocyanate, for cytolysis; (ii) RNasey spin column, with a 
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binding capacity of 100 [ig, for capturing RNA; (iii) wash buffer RWl and RPE for 
RNA precipitation and washing; (iv) RNase-free water for RNA elution. 
3 - mercaptoethanol (2 - ME) 
This reagent was purchased from Sigma Chemical Co., and 10 )liL was added to 
1 niL of lysis buffer of the Qiagen RNeasy Total RNA Extraction Kit prior to cell 
lysis. 
RNase-free DNase Set 
The RNase-free DNase set was purchased from Qiagen and was used for 
on-column digestion of contaminated genomic DNA during RNA purification when 
using the Qiagen RNeasy Total RNA Extraction Kit. The kit consisted of three 
components: RNase-free DNase I with 2500 units/mg, RNase-free buffer, and water. 
2.1.6 Reagents for Polymerase Chain Reaction (PGR) 
AmpliTaa Gold™ with Gg肪Jw”® WXPCR buffer andMsCh_solution 
AmpliTaq Gold DNA polymerase (250 units, 5U/|iL), 10 X PCR reaction buffer 
[100 mM Tris-HCl, pH 8.3, 500 niM potassium chloride (KCl), 15 mM magnesium 
chloride (MgCb), 0.01% (w/v) gelatin] and 25 mM MgCl2 solution were all from 
Applied Biosystems, CA, USA, and stored at -20°C. 
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Tris-ethvlenediamine Tetra-acetic Acid (TE) Buffer 
The buffer was used for primer reconstitution and cDNA dilution. It consisted of 
10 mM Tris-HCl (pH 7.5) and 0.1 mM EDTA in water and was stored at room 
temperature. 
PCR Primers 
The PCR primers for p-actin were purchased from invitrogen. The lyophilized 
primers were reconstituted in TE buffer to obtain a stock concentration of 100 






PCR Nucleotide Mix 
The reagent was purchased from Applied Biosystem. It is in premix form 
containing sodium salts of dATP, dCTP, dGTP and dTTP, each at a concentration of 
10 mM in water at pH 7.5 and stored at -20°C. 
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2.1.7 Reagent for Gel Electrophoresis 
Ethidium Bromide (EtBr) Solution 
The solution was purchased from Gibco and used for detection for agarose gel 
electrophoresis of nucleic acids at 0.5 }ig/mL. 
Tris-Acetate-EDTA (TAE) Electrophoresis Buffer (IPX) 
TAE Buffer (lOX Ultra Pure) was purchased from Invitrogen. It contained 400 
mM Tris-acetate and 10 mM EDTA at pH 8.3. It was diluted to 1 X TAE Buffer in 
agarose DNA electrophoresis. 
DNA Ladders 
One hundred base pair (bp) DNA ladder was purchased from Invitrogen. It was 
supplied ill TE buffer at 1 fig/|LiL and stored at -20°C. The ladder consists of 15 
blunt-ended fragments ranging in length from 100 to 1,500 bp, at 100 bp increments, 
and an additional fragment at 2,072 bp. It can be visualized on 1% to 2% agarose gels 
after ethidium bromide staining. 
Agarose Gel 
Two % agarose gel was prepared by dissolving 2 g agarose powder (Invitrgen) in 
100 mL TAE buffer (1 X) and heated in microwave oven for 15 min. 
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2.1.8 Reagents for Real-Time Polymerase Chain Reaction 
TagMan Universal PGR Master Mix 
The reagent was purchased from Applied Biosystems. It contained the buffer 
components, stabilizers and enzyme at optimal concentrations for real-time PCR 
systems. It was stored in 4°C until use. 
TagMan Reverse Transcription Reasents 
This reagent was purchased from Applied Biosystems. It contained 7 
components: MultiScribe"^ Reverse Transcriptase, RNase Inhibitor, dNTP Mixture, 
Oligo d(T)i6, Random Hexamers, lOX RT Buffer and MgCh Solution. 
Tac/Man 6 - actin Detection Reasent 
This reagent was purchased from Applied Biosystems. It consisted of 4 
components: Human Control DNA, (3-actin Probe (FAM^*^ Probe), p-actin Forward 
Primer, and p-actin Reverse Primer. 
TaaMan TNF-a Detection Reasent 
® 
This reagent was purchased from Applied Biosystems. It contained the TaqMan 
MGB Probes for TNF-a and the corresponding forward and reverse primers that have 
been premixed to a 20 X concentration. 
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2.1.9 Other Reagents 
Enzyme -linked Immunosorbent Assay (ELISA) Kits 
Table 2.4 shows the company from which the human ELISA kit was purchased, 
the sensitivity, and the inter-assay precision (%CV) of the kits. 
Table 2.4 Sensitivities, Intra- and Inter-assay Precision %CV of ELISA Kits 
ELISA kit Company Sensitivity % CV of intra - % CV of inter -
assay precision assay precision 
Soluble CD26 Bender Medsystem 7.26 ng/niL 4.6 9.1 
(BMS235) 
IL-17 R&D Systems Inc. 15 pg/niL 4.1 8.6 
(D1700) 
CXCL13 R&D Systems Inc. 1.64 pg/mL 4.3 9.4 
(DCX130) 
Soluble TNF R&D Systems Inc. 0.77 pg/mL 4.7 8.8 
Receptors (DRTIOO) 
IL-17A Enzyme- linked Immunosorbent Spot (ELISPOT) Kits 
The kit was purchased from eBioscience Coip, CA, USA for the detection of 
IL-17A secreting cells from PBMC. It contained 5 components: pre-titrated capture 
antibody (functional grade with low endotoxin level); pre-titrated biotin-conjugated 
detection antibody; ELISA/ELISPOT; coating buffer powder (reconstitute to IL with 
distilled H2O and 0.22 |j,M filter); 5 X concentrated assay; pre-titrated detection 
enzyme and avidin- Horse Radish Peroxidase (HRP). 
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BD™ Cytometric Beads Array (CBA) Kits 
Human Chemokine CBA Kit I for simultaneous measurement of IL-8 (CXCL8)， 
RANTES (CCL5), MIG (CXCL9), MCP-1 (CCL2) and IP-10 (CXCLIO), and Human 
Inflammation CBA Kit for simultaneous measurement of TNF-a, IL-lp, IL-6, IL-10, 
IL-12p70 and CXCL8 was purchased from BD Biosciences. The kits contained 
cytometric setup beads, phycoerythrin (PE) positive control detector, fluorescein 
isothiocyanate (FITC) positive control detector for compensation settings. It also 
contained five (for chemokine kit) or six (for cytokine kit) populations of capture 
beads with corresponding monoclonal antibodies, PE-conjugated detection reagents, 
standards and wash buffer for cytokines or chemokines detection in plasma or 
supernatants. 
2.2 Methods 
2.2.1 Preparation of Plasma and Purification of Peripheral Blood Mononuclear 
Cells (PBMC) from EDTA-Blood 
Plasma were prepared from EDTA blood by centrifugation at 4°C twice at 2000 g 
for 10 min and then at 16000 g for another 10 min. The cell-free supernatant was 
aliquoted and stored at -70°C for subsequent assay. 
For isolation of PBMC, 6 mL EDTA-blood was diluted with equal volume of 
PBS and slowly layered onto the surface of 12 mL Ficoll-Paque PLUS density 
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gradient solution in two 15 niL centrifuge tubes. The tubes were centrifuged at 800 g 
for 25 min at 18°C. Viable PBMC containing lymphocytes and monocytes were 
collected at the interface between two layers. The cells were then washed twice with 
PBS and resuspend in PBS for subsequent immunofluorescent staining and RNA 
extraction. 
2.2.2 Immunophenotyping of Cell Surface Molecules by Flow Cytometry 
PBMC (5x10^ cells) were washed and resuspended with 3 mL and 100 |iL of 
cold FACS staining medium respectively. The cells were blocked with 2% human 
serum for 20 min at room temperature. 
In direct immunofluorescent staining, the cells were incubated with the 
fluochrome-conjugated antibodies for 45 min in dark at 4°C. For indirect 
immunofluorescent staining, the cells were first incubated with purified 
non-conjugated antibodies, followed by washing before incubating with a 
FITC-conjugated anti-mouse secondary antibody (1:200) for a further 30 min in dark 
at 4°C. 
After a final washing, cells were resuspended in 1% paraformaldehyde. 
Expressions of cell surface antigens were then analysed by flow cytometry 
(FACSCalibur, Beckton Dickinson, CA, USA) in terms of mean fluorescence 
intensity (MFI). 
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2.2.3 Immunophenotyping of Intracellular Molecules by Flow Cytometry 
PBMC (5x10^ cells in 0.5 mL) were fixed with equal volume of 4% 
formaldehyde (Sigma) for 10 min at 37°C. After washing, cells were penneabilized in 
1 mL ice-cold 0.1% saponin (Signma) for 30 min and then stained with 
fluochrome-conjugated antibodies for 45 min in dark at 4°C. Cells were then washed 
and resuspended for analysis suing flow cytometry (FACSCalibur, BD). 
2.2.4 Phosphorylation State Analysis of Intracellular Signaling Molecules 
BDIM PhosFlow activation state analysis (BD Biosciences) was used. Resting, 
phorbol myristate acetate (PMA)- or IL-18-stimulated (20 ng/niL) PBMC (1 x 10^ 
cells in 1 mL) were fixed with an equal volume of pre-warmed BD Cytofix Buffer. 
The fixation was carried out immediately after 12 min stimulation during which the 
cells were incubated at 37°C for 10 min. They were then collected by centrifugation at 
300 g for 5 min. One mL BD PhosFlow Perm Buffer III was added to permeabilize 
the cells for 30 min on ice. Cells were washed twice and resuspended with BD 
Pharmingen Stain Buffer. They were then incubated with mouse anti-human 
phospho-p38, phospho-ERK and phospho-JNK monoclonal antibodies or mouse IgGi 
Isotype at 4°C for 45 min in dark, followed by incubation with FITC-conjugated goat 
anti-mouse IgG secondary antibody (1:200) at 4 � C for 1 hour in dark. The PBMCs 
were co-stained with PE-conjugated mouse anti-human CD4, PerCP-conjugated 
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mouse anti-human CDS and APC-conjugated mouse anti-human CD 19 monoclonal 
antibodies at 4°C for 30 min in dark so as to distinguish the CD4+ T helper 
lymphocyte, CD8+ cytotoxic T lymphocyte and CD 19+ B lymphocyte respectively. 
After a final wash, cells were resuspended in 1 % paraformaldehyde in PBS. The 
expressions of intracellular phosphorylated signaling molecules were then analysed 
by flow cytometry (FACSCalibur, Beckton Dickinson, CA, USA) in terms of mean 
fluorescence intensity (MFI). 
2.2.5 Cytometric Bead Array of Cytokines and Chemokines 
Inflammatory cytokines including IL-ip, TNF-a, IL-12p70, IL-6 and IL-10 and 
chemokines including IL-8 (CXCL8), RANTES (CCL5), MIG (CXCL9), MCP-1 
(CCL2) and IP-10 (CXCLIO), were measured simultaneously with Human 
inflammation CBA Kit and Human Chemokine CBA Kit I respectively (BD 
Phanningen) using flow cytometry (FACSCalibur, BD Biosciences). The kits 
contained 5 chemokines to 6 cytokines bead populations with distinct fluorescence 
intensities. The beads had been coated with capture antibodies specific for different 
cytokines and chemokines. The bead populations could be resolved in the FL3 
channel of flow cytometry. 
Plasma or culture supematants (50 |iL) were incubated with 50 |aL of different 
capture beads mixtures and 50 |iL of PE-conjugated detection antibodies for three 
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hours at room temperature for the sandwich complex formation. After incubation, the 
beads were washed and re-suspended for sample data acquisition using computer 
software Cell Quest (FACSCalibur). The sample results were generated by BD CBA 
analysis software. The principle of CBA is illustrated in Figure 2.1. 
, ^ r h j Sample or standards 
+ ! 
Specific capture beads 
• 
I PE-conjugated H i j detection antibodies 
令 i 
f.， ；洛 •. 
I N C U S A T E 
W A S H 
AC 0 UIR t 
A N A L V Z t 
Figure 2.1 Principle of CBA 
(cited from BD bioscience website http:/八vww.bdbiosciences.com/pharminaen) 
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2.2.6 Total RNA Extraction from PBMC 
Total RNA from PBMC was extracted using RNeasy Mini Kit (Qiagen). PBMC 
(1x10^ cells) were lysed using 0.6mL guanidinium isothiocyanate containing buffer 
that can immediately inactivate RNases to ensure isolation of intact RNA. Ethanol 
(70%) was added at equal volume for RNA precipitation. The sample was then 
applied to an RNeasy mini spin column where the total RNA binds to the membrane. 
DNase was applied to sample for on-column digestion of DNA contaminants. 40 |j,l 
RNase-free water was used to elute high quality RNA. 
2.2.7 Reverse Transcription of the Extracted Total RNA 
Extracted total RNA was reverse transcribed into first-stranded complementary 
DNA (cDNA) using TaqMan Reverse Transcription Reagents (Applied Biosystems) 
according to the instruction of manufacturer. 
2.2.8 Real-time Polymerase Chain Reaction 
Normalization of cDNA Usins 0-actin 
For the real-time PCR analysis, approximately 50 ng of cDNA was applied for 
each reaction. Therefore, the cDNA have to be normalized by a housekeeping gene, 
P-actin, by comparison with PCR amplification. The reaction mixture containing (1)3 
mM MgCl2, (2) 200 ^M dNTPs, (3) 1 unit of AmpliTaq Gold DNA polymerase, (4) 
50 pmol of 5’ and 3’ p-actin primers in PCR reaction buffer was mixed with the 
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cDNA and PCR was performed by PTC-200 DNA Engine™ (MJ Research Inc, MA, 
USA). The condition of PCR amplification was: (step 1) 1 min for 94°C for 
denaturing, (step 2) 60°C for annealing and (step 3) 72°C for elongation. The reaction 
was allowed to repeat 35 times after an initial 12 min denaturation at 94°C. 
After the amplification reaction, PCR products were electrophoresed on 2 % 
agarose gel in 1 X TAE buffer (pH 8.0) and stained with EtBr. The relative intensities 
of electrophoretic bands were analyzed with Gene Genius Gel Documentation System 
(Syngene Inc, Cambridge, UK). 
Real-Time PCR Analysis 
Relative quantitative assay was used to compare gene expression of human 
TNF-a in SLE patients' PBMC with healthy controls. For this assay, standard curves 
with known concentration of total cDNA were prepared for both the target and the 
endogenous reference (p-actin). For each experimental sample, the amount of human 
TNF-a and p-actin was determined from their corresponding standard curve. Then, 
the amount of human TNF-a was divided by p-actin to obtain a normalized target 
value. 
The relative gene expression of human TNF-a in SLE patients' PBMC was 
quantified by real-time PCR with the use of ABI 48-well StepOne™ Real Time PCR 
System (Applied Biosystems). Real-time PCR was performed in a 20 |LIL reaction 
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mixture containing TaqMan Universal PGR Master Mix, TaqMan P-actin / TNF-a 
Detection Reagent and cDNA sample. The real-time PGR reaction was performed at 
fast mode: (step 1) 95�C for 1 sec to denature cDNA, (step 2) 60°C for 20 sec to allow 
the TaqMan Probe and Primers to anneal to the denatured cDNA. Step 1 and 2 were 
repeated 30 times after an initial 20 sec denaturation at 95°C. 
2.2.9 Enzyme-Linked Immunosorbent Assay (ELISA) 
Plasma or supernatant level of cytokines and chemokines aforementioned were 
quantified by using their corresponding ELISA kits. Protocols were carried out as 
described by manufacturers. Enzymatic products were measured by using VICTOR V 
Multilabel Plate Reader (Perkin Elmer Life and Analytical Sciences, Inc., CT, USA). 
2.2.10 Enzyme-Linked Immunosorbent Spot (ELISPOT) 
PBMC was preserved using Cryostar^M freezing medium (U-CyTech 
Biosciences Corp, Yalelaan, Netherlands) at -80°C until the assay. For assay, the 
number of IL-17A secreting cells in PBMC (1 x 10^ cells) upon 24 h activation by 
PMA (50 ng/ml) and ionomycin (1 |ag/ml) in polyvinylidene difluoride filter 96-well 
plate (Millipore Corp, MA, USA) was detected using Human IL-17A ELISPOT kit 
(eBioscience) according to the operation manual. The number of colored spots (lOX) 
was counted using a Nikon SMZ 1000 Dissection Microscope (Nikon, CA, USA). 
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2.2.11 Statistical Analysis 
Data were analyzed by Mann-Whitney U Test for comparing two groups of 
non-parametric numerical variables. Correlations were tested by using Spearman's 
coefficient of correlation. P value less than 0.05 were considered as statistically 
significant. 
All comparisons were made two-tailed and statistical analysis was performed 
with statistical software GraphPad Prism (GraphPad Software Inc, CA, USA) and 
Statistical Package for Social Sciences (SPSS) for Windows (version 9.0, SPSS Inc, 
IL, USA). 
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Chapter 3 
B Cell Chemokine CXCL13 in SLE 
3.1 Introduction 
B lymphocyte chemoattractant (BLC), also known as CXCLl3，is a member of 
the CXC subtype of the chemokine superfamily. It is mainly produced by peritoneal 
macrophages, dendritic cells (DC) and cells in the omentum [Ansel et al., 2002; 
Vissers et al., 2001], and is selectively chemotactic for B lymphocytes including both 
the B1 and B2 subsets [Ansel et al., 2002; Legler et al.’ 1998]. CXCL13, together 
with its receptor CXCR5, controls the organization of B lymphocytes within follicles 
of lymphoid tissues [Ansel et al., 2000], and are highly expressed in the liver, spleen, 
lymph nodes and gut of human [Legler et al., 1998]. Recent studies have also reported 
that CXCLl 3 can induce trafficking of follicular T helper lymphocytes (TFH), a 
CXCR5+ T lymphocytes involved in IgG responses [Schaerli et al., 2000; Breitfeld et 
al., 2000]. B1 lymphocytes are distinguishable from the re-circulating conventional B 
(B2) lymphocytes in terms of tissue distribution, cell surface phenotype and function 
[Hayakawa et al., 2000]. Cell surface expression of CXCR5 on B1 lymphocytes was 
significantly higher than B2 lymphocytes. The accumulation of B1 lymphocytes in the 
peritoneal cavity and spleen are responsible for the body-cavity immunity and the 
production of autoantibody for the development of autoimmune disease in the murine 
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model [Ansel et al., 2002; Hayakawa et al.，2000; Sato et al., 2004]. Elevated levels 
of B1 lymphocytes have been reported in patients with autoimmune disorders such as 
Sjogren's syndrome and rheumatoid arthritis [Dauphinee et al., 1988; Plater-Zyberk et 
al., 1985]. Previous studies showed that CXCL13 was over-expressed by 
CDl lb+CDl l c+ DC in the target organs including thymus and kidney for the 
chemoattraction of B1 lymphocytes in lupus mice [Ito et al., 2004; Ishikawa et al, 
2001; Ishikawa et al., 2007; Sato et al., 2004]. Therefore, elevated expression of 
CXCL13 by meloid DC may play a crucial role in breaking the immune tolerance in 
the target organs, which result in activation of autoreactive Th lymphocytes and 
recruitment of autoantibody producing B lymphocytes in the development of murine 
lupus [Ishikawa et al.’ 2001; Sato et al., 2004; Ishikawa et al., 2007]. However, the 
aberrant production of CXCL13 in SLE patients was not fully elucidated. To further 
understand the immunopathological roles of CXCL13 in SLE, plasma concentrations 
of CXCL13 and its correlation with disease severity in SLE patients was investigated 
in this study. 
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3.2 Methods 
Plasma concentrations of CXCL13 and sTNFRl in SLE patients and control 
subjects were measured by enzyme-linked immunosorbent assay (ELISA) using 
Quantikine colorimetric reagent kit ( R & D Systems, MN, USA). 
Gene expression of human TNF-a in PBMC of SLE patients and healthy 
controls was quantified by real-time PGR with the use of ABI 48-well StepOne™ 
Real Time PGR System (Applied Biosystems). 
Numerical data were expressed as median (interquartile range, IQR) if they were 
not in Gaussian distribution. Difference in plasma concentration among groups was 
compared with Mann Whitney rank sum test. Spearman's rank correlation test was 
used to assess the correlations of plasma chemokine with SLEDAI score. Statistical 
analysis was performed using SPSS statistical software for Windows, version 9.0. 
Probability values (p) < 0.05 were considered as significant. 
3.3 Results 
3.3.1 Characteristics of SLE Patients and Control Subjects 
Thirty-five Chinese SLE patients (31 females and 4 males) were recruited at the 
Rheumatology Out-patient Clinic of the Prince of Wales Hospital, Hong Kong. 
Twenty-three healthy Chinese volunteers were recruited as controls. Twelve mL of 
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EDTA venous peripheral blood were collected from each patient and control subject. 
The characteristic of SLE patients and control subjects were listed in Table 3.1. 
3.3.2 Expression of Plasma CXCL13 
As shown in Figure 3.1，plasma CXCL 13 concentration was significantly higher 
in SLE patients than control subjects [median (IQR), SLE: 95 (70-159) vs control: 45 
(38-63) pg/mL; p < 0.0001]. Figure 3.2 shows that CXCL13 concentration was 
positively correlated with SLEDAI score in SLE patients (r = 0.399，p < 0.05). 
3.3.3 Gene Expression of TNF-a in PBMC 
As shown in Figure 3.3, there was no significant difference in the relative gene 
expression of TNF-a in PBMC between SLE patients and control subjects [SLE: 0.33 
(0.21-0.81) vs control: 0.35 (0.28-0.42)]. 
3.3.4 Expression of sTNFRl in Plasma 
In Figure 3.4，compared with control subjects, sTNFRl concentrations were 
significantly higher in SLE patients than in control subjects [SLE: 842 (716-946) vs 
control: 478 (412-528) pg/mL; p < 0.001]. 
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Table 3.1 Characteristics of SLE patients and control subjects 
SLE Control 
Number 35 23 
Sex (female/male) 31/4 23/0 
Age，year (mean 土 SD’ range) 41 士 10 46 土 7 
(21-65) (25 - 57) 
Duration of diagnosis, year, 12 士 7 
NA 
Mean 土 SD (range) (0.49-30) 
SLEDAI Score 3.1 ± 3 
NA 
Mean 士 SD (range) (0-12) 
Treatment with prednisolone 
33 (94.3) Patients, no. (%) NA 14.1 ±55.6 Daily dose, mg (2.5-500) 
Mean 士 SD (range) 
Treatment with hydroxychloroquine 
Patients, no. (%) 11(31.4) 
Daily dose, mg 217.3 ± 56.8 NA 
Mean 土 SD (range) (20-300) 
Treatment with azathioprine 
Patients, no. (%) 12(34.3) 
Daily dose, mg 63.9 ±27.2 NA 
Mean 士 SD (range) (25-100) 
Values are in mean 士 SD (range); NA: not applicable 
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Figure 3.1 Expression of CXCL13 in SLE patients and control subjects. 
Plasma concentration of CXCL13 from the peripheral blood of SLE patients and 
control subjects (CTL) was determined by ELISA. Difference in plasma concentration 
among groups was compared with Mann Whitney rank sum test. Results are presented 
with Box-and-Whisker plots, *** p < 0.001. 
1000-1 
i r = 0.399 




JS 200- ^ ^ CL • • * I • 
OH 1 1 1 1 1 
0 5 10 15 20 25 
SLE disease severity index (SLEDAI) 
Figure 3.2 Correlation between plasma CXCL13 and SLE disease activity. 
The correlation between plasma CXCL13 and SLEDAI score was assessed using 
Spearman's rank correlation test. Results are presented with scatter plot, r = 0.399, p = 
0.032. 
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Figure 3.3 Relative gene expression of TNF-a in SLE patients and control 
subjects. Relative gene expression of TNF-a from PBMC of SLE patients and 
control subjects (CTL) was calculated by dividing the mRNA expression of TNF-a by 
an endogenous housing keeping gene (p-actin). Difference in gene expression among 
groups was compared with Mann Whitney rank sum test. Results are presented with 
Box-and-Whisker plots. 
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Figure 3.4 Expression of sTNFRl in SLE patients and control subjects 
Plasma concentration of sTNFRl from the peripheral blood of SLE patients and 
control subjects (CTL) were determined by ELISA. Difference in plasma 
concentration among groups was compared with Mann Whitney rank sum test. 
Results are presented with Box-and-Whisker plots, *** p < 0.001. 
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3.4 Discussion 
SLE has been regarded as a Th2 cytokine-mediated disease characterized by 
autoantibody production and immune complex deposition [Mohan et al., 1993]. There 
have been reports showing that B cell chemokine CXCL13 is ectopically and highly 
expressed in the thymus and kidneys of SLE mice [Ishikawa et ai, 2007]. However, 
the role of CXCL13 in human has not been fully elucidated. In this study, we have 
confirmed a significant increase in plasma concentration of CXCL13 in SLE patients 
that was positively correlated with disease severity (Figure 3.1 and 3.2). We also 
found that plasma CXCL13 concentrations in SLE patients did not show any 
correlation with the dosages of prednisolone, hydroxychloroquine and azathioprine 
(data not shown). The elevated production of CXCL13 was not observed in allergic 
asthmatic and psoriasis patients, therefore indicating the specific role of CXCL13 in 
autoimmune disease [Fulkerson et al., 2004]. Recently, it has been reported that 
TNF-a plays a crucial role in the recruitment and maturation of DC into CXCL13 
producing DC during the development of SLE [Ishikawa et al” 2002; Ishikawa et al” 
2007]. Therefore, we have measured the plasma level of TNF-a in peripheral blood of 
SLE patients as well as their gene expression level in PBMC. However, the 
concentration of TNF-a in plasma was below detection limit (data not shown), and 
the gene expression level of human TNF-a in PBMC of SLE patients was not 
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significantly different from normal controls (Figure 3.5). Since local consumption and 
degradation of TNF-a by the inflamed tissue may account for the low expression 
level of TNF-a in the peripheral blood, we measured the plasma concentration of 
soluble TNF Receptor 1 (sTNFRl) in plasma, and it was confirmed that sTNFRl was 
significantly increased in SLE patients. Since sTNFRl is produced at the sites of 
inflammation and TNF-a/sTNFR system are closely related to the cardiovascular and 
renal manifestations in SLE [Turan et al., 2008; Svenungsson et al.’ 2003], our results 
may provide insight for imniunopathological mechanism of the aberrant 
TNF-a/sTNFR pathway in relation to the elevated CXCLl3 from activated DC in 
SLE (Figure 3.1). 
A recent report has demonstrated that B-cell-activating factor of the TNF family 
(BAFF), which mainly expressed on activated mDC and T lymphocytes, was 
significantly increased in SLE [Morimoto et al” 2007]. In another study, BAFF was 
reported to increase the chemotactic response of primary human B lymphocytes to 
CXCLl3 [Badr et ai, 2008]. The synergy between CXCLl3 and BAFF may therefore 
have important implications for B lymphocyte activation in SLE by stimulating T 
lymphocyte-dependent B lymphocyte autoantibodies production [Badr et al., 2008]. 
Together with the findings from Ishikawa et al., we proposed that TNF-a may 
involve in the activation of mDC to release CXCLl3 and BAFF, which can act 
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synergistically to induce B-cell proliferation, immunoglobulin isotype switching, and 
plasma cell differentiation through the interaction with CXCR5 (CXCL13 receptor) 
on B cell (figure 3.1). To support our hypothesis, we will expand our study by 
investigating the ex vivo production of CXCL13 and BAFF by peripheral mDC upon 
TNF-a stimulation in SLE patients. In addition, we will measure the expression of 
CXCL13 receptor (CXCR5) on B lymphocytes upon TNF-a activation so as to 
understand the aberrant TNF-a-mDC-CXCLl 3-B cell axis in SLE patients. 
In view of the recent developments of monoclonal antibody against BAFF (e.g.: 
belimumab) that can effectively deplete pathogenic B lymphocytes and their 
dependent autoantibody production, B cell-directed therapies represent promising 
treatments for various autoimmune disorders [Levesque et al” 2008; Sabahi et al., 
2006]. Our results of the pathological role of elevated production of CXCL13 and 
sTNFRl may provide insight for the pathologic B lymphocyte responses and help to 
investigate treatments of SLE. 
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Figure 3.1: Proposed TNF-a-mDC-CXCL13-B cell axis 
TNF-a may involve in the maturation of mDC into CXCLlS-releasing mDC. 
CXCL 13，together with the BAFF, can induce B-cell proliferation, immunoglobulin 
isotype switching, and plasma cell differentiation through the interaction with CXCR5 
(CXCL 13 receptor) on B cell. 
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Chapter 4 
T Lymphocyte Co-stimulatory Molecule CD26 in SLE 
4.1 Introduction 
CD26, a T cell co-stimulatory molecule with dipeptidyl peptidase IV (DPPIV) 
activity, is a 110-kDa transmembrane glycoprotein responsible for the degradation of 
interferon (IFN)-Y-induced chemokine such as CXCLIO [Lambeir et al., 2003]. Cell 
surface CD26 is expressed on various cell types including epithelial cells, endothelial 
cells, activated T helper (Th) lymphocytes, invariant natural killer T (iNKT) 
lymphocytes and B lymphocytes [Lambeir et al,, 2003]. CD26 also circulates in 
plasma as soluble form (sCD26) with dipeptidyl peptidase IV activity, which lacks the 
cytoplasmic tail and transmembrane region, for the enhancement of antigen-induced 
T-cell proliferation [Tanaka 1994; Thompson 2007]. CD26 can act as peptidase, 
co-stimulatory molecule, or receptor for adenosine deaminase, collagen and 
fibronectin, and involve in multiple immunopathological roles in leukocyte homing 
and inflammation [Augustyns, 1999; Cheng, 1998; Gutheil, 1994; Ohtsuki, 1998; 
Wronger, 1997]. Therefore, CD26 is regarded as a crucial molecule involved in the 
pathogenesis of various diseases such as infection by human immunodeficiency virus 
[Morimoto et al.’ 1994] and Mycobacterium tuberculosis [Oshikawa et al., 2001], 
breast cancer [Huang et al.’ 2008] and diabetes [Mcintosh, 2008]. Elevated expression 
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of CD26+CD4+ T lymphocytes in peripheral blood and cerebrospinal fluid was 
reported in patients with multiple sclerosis (MS) [Constantinescu et aL, 1995; Jensen 
et al., 2004]. Our previous study also confirmed that cell surface CD26 and sCD26 
were increased in allergic asthma, which contributed to the Th2-mediated airway 
inflammation [Lun et aL, 2007]. In vitro study using potent synthetic inhibitors and 
animal studies on CD26-deficient mice identified that CD26 can act as a target for 
immunosuppressive therapy [Reinhold et al.’ 2002; Wrenger et al.’ 2000]. However, 
CD26 expression in patients with rheumatoid arthritis, murine model of arthritis and 
encephalomyelitis (EAE) demonstrated a decreased circulating concentration of 
sCD26 [Busso et al., 2005; Preller et al., 2007]. CD26-deficient mice also show an 
aggravated EAE severity due to a deficit in the regulatory mechanisms that are 
elicited by natural ligands of CD26 for limiting Thl immune response via 
transforming growth factor (TGF)-pl production [Preller et aL, 2007]. A recent study 
has reported that serum sCD26 in SLE patients was negatively correlated with disease 
activity [Kobayashi, 2002]. The down-regulation of sCD26 may reduce truncation of 
the Thl chemoattractants such as CXCLIO, thereby exacerbating Thl-related 
inflammation in SLE. Therefore, it is suggested that CD26 may have a protective role 
in autoimmune inflammation and SLE. However, the underlying mechanisms of its 
function in healthy and SLE subjects have not been fully elucidated. 
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Natural killer T (NKT) lymphocyte is a subset of T lymphocytes that exhibit both 
properties of natural killer cells and conventional T lymphocytes. Whereas 
conventional T lymphocytes respond to peptide-MHC ligand, the NKT lymphocytes 
with the canonical T cell receptor (TCR) sequence recognize a glycolipid antigen in 
association with the monomorphic CD Id molecule, a major histocompatibility 
complex (MHC) class I like molecule expressed on dendritic cells, monocytes, and 
subgroups of B cells [Kronenberg, 2005]. The majority of the NKT lymphocyte 
belongs to iNKT lymphocytes, which expresses invariant TCR [Porcelli et al., 1993]. 
Upon activation, iNKT lymphocyte produces a variety of cytokines, including Thl 
cytokines such as IL-2, tumor necrosis factor-a and IFN-y as well as Th2 cytokines 
including IL-4, IL-5, IL-10 and IL-13, which are thought to play regulatory roles in a 
wide range of immune responses [Mercer, 2005; Sakuishi et al； 2007]. Studies on 
autoimmune patient with MS reported that the number of total iNKT lymphocytes 
was down-regulated in the peripheral lymphocytes, and the numeric reduction was 
more remarkable in remission than relapse of MS [Araki et al., 2003]. As suggested 
by Araki et al., CD4+iNKT lymphocytes are functionally Th2-biased while 
CD4-iNKT lymphocytes are neither Thl- or Th2-biased [Araki et al, 2003]. 
Therefore, it was regarded that the Tli2-biased iNKT lymphocytes may play a 
protective role in Thl-mediated inflammatory responses, while dysfunction of iNKT 
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lymphocytes may instigate the manifestation of various autoimmune diseases. 
To further elucidate the immunopathological role of CD26 and iNKT 
lymphocytes in the pathogenesis of SLE, we investigated the plasma concentration of 
sCD26 and circulating number of iNKT subset in the peripheral blood lymphocytes. 
Cell surface expression of CD26 on monocytes, CD4+ and CD8+T lymphocytes, 
CD19+B lymphocytes and CD3+Va24+Vpil+ iNKT lymphocytes in SLE patients 
was also measured. 
4.2 Methods 
Plasma concentrations of sCD26 in SLE patients and control subjects were 
measured by ELISA (Bender MedSystems). PBMCs were incubated with fluorescein 
isothiocyanate (FITC) conjugated CD26 specific monoclonal antibody (mAb), 
followed by phycoerythrin (PE) conjugated CD4, allophycocyanin (APC) conjugated 
CD 19 and peridinin-chlorophyll-proteiii (PerCP) conjugated CDS antibodies (BD 
Biosciences). FITC conjugated mouse immunoglobulin (Ig)G was used as isotypic 
control. The typical forward and side scatter gates for lymphocytes were set to 
exclude contaminating cells from the analysis. 
For the study of cell surface expression of CD26 on iNKT lymphocytes, PBMC 
from SLE patients and control subjects were incubated with purified CD26 specific 
mAb (BD Pharmingen) followed by APC conjugated secondary antibody (R&D 
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Systems). These cells were subsequently incubated with PerCP conjugated CD3 (BD 
Pharmingen), FITC-conjugated Va24 and PE conjugated Vpl 1 antibodies (Beckman 
Coulter) for the identification of iNKT lymphocytes. • 
Cell surface expression of human CD26 on monocytes, CD4+ and CD8+T 
lymphocytes, CD19+B lymphocytes and CD3+Va24+Vpil+ iNKT lymphocytes 
were analyzed by flow cytometry (BD FACSCalibur). A total of 5000 events were 
collected and results are expressed as percentage increase comparing with the isotypic 
control. 
Circulating number of iNKT subset in the peripheral blood lymphocyte was 
analyzed by flow cytometry with anti-CD3, anti-Va24 and anti-V(311 cell surface 
staining. 
Difference in plasma concentration between SLE and control groups was 
analyzed with Mann Whitney rank sum test. Spearman's rank correlation test was 
used to assess the correlations between different parameters. Statistical analysis was 
performed using the statistical package for the Social Sciences (SPSS) statistical 
software for Windows, Version 9.0. Probability values {p) < 0.05 were considered as 
significant. 
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4.3 Results 
4.3.1 Characteristic of SLE Patients and Control Subjects 
Twenty-three female Chinese SLE patients were recruited at the rheumatology 
out-patient clinic of the Prince of Wales Hospital, Hong Kong. Fourteen female 
Chinese age-matched volunteers were recruited as controls. Twelve mL of EDTA 
venous peripheral blood were collected from each patient and control subject. The 
characteristics of SLE patients and control subjects were listed in Table 4.1. 
4.3.2 Expression of Human CD26 in Plasma 
As shown in Figure 4.1，plasma concentrations of sCD26 showed no significant 
difference between SLE patients and normal control subjects [median (IQR), SLE: 
490 (372 一 609) vs control: 461 (370 — 572) ng/niL; p > 0.05]. 
4.3.3 Cell Surface Expression of CD26 on Monocytes, CD4+T, CD8+T, CD19+B 
and iNKT Lymphocytes 
Figure 4.2 shows that there was no significant difference in cell surface 
expression of CD26 on monocytes [SLE: 35 (16 — 55) vs control: 29 (18 — 52); p > 
0.05], CD8+ T lymphocytes [SLE: 188 (144 - 242) vs control: 171 (96 - 212); p > 
0.05] and CD 19+ B lymphocytes [SLE: 31 (11 — 88) vs control: 64 (33 — 93); p > 
0.05]. However, there was a significant down-regulation in cell surface expression of 
CD26 on CD4+ T lymphocytes [SLE: 531 (271 - 736) vs control: 1084 (687 - 1478)， 
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p < 0.001]. The cell surface expression of CD26 was also significantly reduced on 
iNKT lymphocytes of SLE patients [SLE: 39 (17 - 57) vs control: 64 (32 - 172), p < 
0.05]. 
4.3.4 Circulating Number of iNKT Lymphocytes 
As shown in Figure 4.3，there was a significant reduction in the number of iNKT 
lymphocytes per 10,000 peripheral lymphocytes in SLE patients compared with 
control subjects [SLE: 7 (2-52) vs control: 43 (28-116), p < 0.05]. 
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Table 4.1 Characteristics of SLE Patients and Control Subjects. 
SLE Control 
Number 23 14 
Sex (female/male) 23/0 14/0 
Age，year (mean土 SD，range) (^士_ 工 ' (25 ' -57) 
Duration of diagnosis, year, 12 土 7 
Mean ± SD (range) (0.49 - 30) 
SLEDAI Score 4.2 ±3 .1 
Mean ± SD (range) (0 - 12) 
Treatment with prednisolone 
Patients, no. (%) 22 (95) 
Daily dose, mg 8.2 ±1 NA 
Mean 土 SD (range) (5 - 30) 
Treatment with hydroxychloroquine 
Patients, no. (%) 
， � 217.3^56.8 NA Mean 士 SD (range) (20-300) 
Treatment with azathioprine 
Patients, no. (%) 6(26.71) 
Daily dose, mg 56.3 士 31.5 NA 
Mean ± SD (range) (25 - 100) 
Values are presented as mean j^SD (range); NA: not applicable 
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Figure 4.1 Expression of human CD26 in SLE patients and control subjects. 
Plasma concentration of human sCD26 from venous peripheral blood of SLE patients 
and control subjects (CTL) were determined by ELISA. Difference in plasma 
concentration among groups was compared with Mann Whitney rank sum test. 
Results are presented with box-and-whisker plot. 
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Figure 4.2 Cell surface expression of human CD26 in SLE patients and control 
subjects. Cell surface expressions of CD26 on (A) monocytes, (B) CD4+T 
lymphocytes, (C) CD8+T lymphocytes, (D) CD19+B lymphocytes and (E) iNKT 
lymphocytes were analyzed by flow cytometry. Difference in CD26 expression 
between SLE patients and control subjects (CTL) was compared with Mann Whitney 
rank sum test. Results are presented with box-and-whisker plot, *p < 0.05, ***p < 
0.001. 
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Figure 4.3 Circulating number of iNKT lymphocyte in SLE patients and 
control subjects Number of iNKT lymphocytes in 10,000 lymphocytes were 
analyzed by flow cytometry. Difference in cell number between SLE patients and 
control subjects (CTL) was compared with Mann Whitney rank sum test. Results are 
presented with box-and-wliisker plot (*p < 0.05). 
4.4 Discussion 
The activity of cytokines and chemokines mainly depends on their production, 
secretion, stability and degradation, and the presence of peptidases can play crucial 
role in the regulation of the bioavailability of cytokines and chemokines at the site of 
inflammation. It has been reported that soluble and cell surface CD26 can rapidly 
truncate IFN-y-induced Thl chemokines (e.g.: CXCL9 and CXCLIO), which 
influence their ability to induce signaling without affecting their receptor binding 
[Baggiolini, 1998]. The truncated cytokines are converted to isoforms containing no 
inflammatory activity, thus abolishing the chemotaxis of Thl lymphocytes [Proost et 
al., 2001]. It has been suggested that SLE is a Th2-polarized disease because of its 
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production of auto-antibodies [Mohan et al., 1993]. However, other studies have 
demonstrated that Thl responses including IL-12 and IFN-y are also significantly 
elevated in SLE [Viallard et al., 1999; Tokano et al.’ 1999], causing the inflammatory 
exacerbation. 
Although there was no significant difference between plasma concentration of 
sCD26 ill SLE patients and control subjects (Figure 6.1), we found that cell surface 
expression of CD26 was significantly reduced on CD4+T lymphocytes and iNKT 
lymphocytes (Figure 6.2) but not on monocytes, CD19+B lymphocytes, CD8+T 
lymphocytes. Furthermore, concentration of sCD26 and cell surface expression of 
CD26 on different studied lymphocyte subsets did not exhibit any significant 
correlation with the disease activity (all p > 0.05, data not shown). Together with our 
previous findings of the positive correlation between Thl-related cytokines and 
chemokines such as IL-12, IL-18 and CXCLIO with SLEDAI [Lit et al., 2006; Wong 
et al., 2002], we suggest that the decreases in cell surface expression of CD26 on 
CD4+T lymphocytes and iNKT lymphocytes may modulate the immunopathogenesis 
by up-regulating the activity of Thl chemokines in SLE. Our data are actually in line 
with the previous observation that CD26 is negatively associated with 
antigen-induced arthritis in the CD26-deficient murine model [Busso et al, 2005], 
suggesting that CD26 may act as a negative regulatory molecule in autoimmunity. 
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Previous studies have also reported that T lymphocytes from CD26 deficient mice 
showed a deficiency TGF-pl production. Decreased TGF-pl responsiveness upon 
challenge by super-antigen such as myelin oligodendrocyte glycoprotein peptides may 
be the primary cause of Thl lymphocyte proliferation [Preller et al., 2007]. Another 
study by Racke et al. also suggested that treatment with anti-TGF-p antibodies can 
exacerbate severity of autoimmune disease such as EAE, whereas TGF-p treatment 
can suppress the disease activity [Racke et al,, 1991]. CD4+CD25+ regulatory T 
(Treg) lymphocytes, a central modulator in maintaining immunologic homeostasis, 
can suppress T lymphocyte activity by the production of TGF-(3. Valencia et al. also 
demonstrated that Treg lymphocytes were deficient in patients with active SLE, 
suggesting that reduced Treg responsiveness or decreased Treg differentiation may 
account for the down-regulation of TGF-P, which can subsequently exacerbate the 
SLE disease activity or other autoimmune disease [Valencia et al., 2007]. The 
reduction of cell surface CD26 on CD4+T lymphocytes may be due to the 
down-regulation of CD26 on Treg lymphocytes and iNKT in SLE patients (Figure 
6.2). Since increased Thl immunity and defective TGF-P 1 production may cause 
exacerbation of autoimmune disease such as experimental autoimmune 
encephalomyelitis (EAE) and SLE, the exact pathophysiological function of CD26 of 
Treg lymphocytes requires further investigation. 
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The Thl/Th2 cytokines imbalance caused by NKT lymphocyte is also thought to 
trigger immuno-dysregulation. As reported by Askuishi et al., in the presence of IL-2, 
CD4+iNKT lymphocytes preferentially produce Th2 cytokines IL-5 and IL-13 when 
co-cultured with CDld+ antigen presenting cells [Sakuishi et al.’ 2007]. Another 
report by Sen et al. demonstrated that iNKT lymphocytes in the blood of asthmatic 
patients selectively expressed CCR9 and large numbers of CCR9+ iNKT lymphocytes 
were present in bronchial-biopsy samples from asthma patients but not control 
subjects [Sen et al.’ 2005]. They also demonstrated that conventional CD3+ T 
lymphocytes could be polarized to Th2 phenotype by cell-to-cell contact with iNKT 
lymphocytes, with enhanced expression of CCR9, from patients with asthma [Sen et 
al., 2005]. Moreover, our previous study of asthmatic patients demonstrated that 
increased expression of CD26 on iNKT lymphocytes may contribute, at least partly, to 
the inflammatory process and Th2 predominance in the inimunopathogenesis of 
allergic asthma [Lun et al., 2007]. Collectively, these findings suggest that increase in 
CD26+iNKT lymphocytes might facilitate Th2-biased response and we suggested that 
iNKT may have a protective role in Thl-mediated inflammatory disease. In parallel 
with the lymphopenia usually associated with SLE [Beyan, 2007], we showed that 
total iNKT lymphocytes were significantly reduced in the peripheral blood of SLE 
using anti-Va24 and anti-Vpil staining (Figure 6.3). Our data is also supported by 
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the previous report of the reduction iNKT number derived from autoimmune patients 
such as MS, which suggested a Th2-baised response in CD4+iNKT lymphocytes 
while the CD4-iNKT lymphocytes remain neutral towards Thl or Th2 [Araki et al., 
2003]. Another study reported that raised IgG levels in SLE patients were associated 
with low frequencies of NKT lymphocytes [Green et al, 2007]. The reduction of 
iNKT lymphocytes might possibly due to a defect of the co-stimulatory pathways, 
which hindered iNKT expansion and activation. In addition, the cell surface 
expression of CD26 on iNKT lymphocytes was significantly down-regulated in 
patients with SLE (Figure 6.2). Since CD26 can function as a peptidase as well as 
co-stimulatory molecule, we suggest that CD26 deficiency may reduce the 
proliferation and function of iNKT lymphocytes, which in turn shift the conventional 
T lymphocytes toward a Thl-biased response and exacerbate SLE pathogenesis. This 
present data allow us to speculate that iNKT lymphocytes can relate with the 
immunopathological roles and immunomodulatory mechanism in SLE. Enhancement 
of NKT lymphocyte activity maybe a novel therapeutic approach towards 
autoimmune disease and CD26 may be a potential therapeutic target for immune 
disorders [Thompson 2007; Green 2007]. 
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Chapter 5 
Thl7 Lymphocytes and Expression of IL-17 in SLE 
5.1 Introduction 
A major characteristic of SLE is the production of autoantibodies by the 
hyperactivated B lymphocytes. It has been suggested that the disease is Th2-biased, as 
exemplified by the up-regulation of Th2 cytokines IL-4 and IL-10 in the peripheral 
blood mononuclear cell (PBMC) of SLE patients [Mosmann et ai, 1989]. However, 
previous study conducted by our group demonstrated elevated Thl cytokine 
expression in SLE patients, suggesting that both Thl and Th2 cytokines are important 
in the pathogenesis and pathophysiology [Wong et al., 2000]. 
Apart from the conventional Thl and Th2 lymphocytes, a novel Th subset, Thl7 
lymphocytes, has also been discovered. It is characterized by a unique cytokine 
signature including IL-17A, IL-17F, IL-21 and IL-22. Emerging data suggest that 
Thl7 lymphocytes are highly auto-pathogenic and can induce tissue inflammation and 
autoimmune disease. [Harrington et al., 2005; Kom et al. 2007]. 
IL-17A and IL-17F, produced primarily by Thl7 lymphocytes, are the most 
studied members of the IL-17 cytokine family. They are pleiotropic proinflammatory 
cytokines that can enhance T cell priming and stimulates epithelial, endothelial and 
fibroblastic cells to produce multiple proinflammatory cytokines such as IL-6, G-CSF, 
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GM-CSF, IL-ip, TGF-P and TNF-a as well as chemokines including CXCLl, CXCL8 
and CCL2 [Kawaguchi et al” 2004]. 
IL-23, a novel cytokine involved in promoting cellular immunity, is also closely 
related to Thl7 lymphocytes. It is a heterodimeric cytokine composed of a unique pi 9 
subunit and a common p40 subunit shared with IL-12 [Lankford et al., 2003]. In 
contrast to IL-12, IL-23 does not promote the development of Thl lymphocytes, but 
involved in the expansion of a Thl7 lymphocyte population [Kikly et al., 2006]. In 
animal studies, IL-23 dependent Thl7 lymphocyte can invade the target organ and 
promote the development of organ-specific autoimmune inflammation [Cua et al., 
2003]. On the other hand, IL-23-deficient mice are resistant to experimental 
autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) disease 
development [Zhang et al., 2003]. 
For better understanding the involvement of IL-23 in the IL-23/IL-17 
auto-inflammatory axis, we investigated the immune response of the activated PBMC 
by evaluating their ex vivo production of IL-17A upon costimulation in the presence 
of IL-23, anti-CD3 and anti-CD28 and examined their significance in SLE patients. 
To further elucidate the immunopathological role of Thl 7 in autoimmune disease, we 
have also measured the number of circulating Thl 7 lymphocytes in the peripheral 
blood lymphocytes of SLE patients. Studies on Thl7 subset and its relevant issues 
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offered potential therapeutic targets for patients with autoimmune diseases, which 
may have significant impacts in the prevention and treatment of SLE. 
5.2 Methods 
PBMC from SLE patients and control subjects were purified by ficoll gradient 
centrifugation. For the ex vivo induction of IL-17A, PBMC was incubated with or 
without anti-CD3 and CD28 monoclonal antibody (BD Pharmingen, each 1 |ig/mL) 
and IL-23 (Peprotech, 20 ng/mL) for 24 li at 37 °C in a 5% CO2 atmosphere. After 
incubation, the cell free supernatant of ex vivo culture was harvested and stored at -70 
�C for subsequent ELISA (R&D Systems). 
Circulating IL-17A secreting cells was enumerated by Enzyme-linked 
immunosorbent spot (ELISPOT). PBMC was preserved using Cryostar^M freezing 
medium (U-CyTech Biosciences) at -80 °C until assay. For assay, the number of 
IL-17A secreting cells in PBMC (1x10^) upon 24 h activation by phorbol-myristate 
acetate (PMA) (50 ng/ml) and ionomycin (1 |ig/ml) in polyvinylidene difluoride 
(PVDF) filter 96-well plate (Millipore) was detected using Human IL-17A ELISPOT 
kit (eBioscience). The number of colored spots was counted using a dissection 
microscope. 
Numerical data were expressed as median (IQR) if they were not in Gaussian 
distribution. Difference in IL-17A and Thl7 lymphocyte expression among groups 
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was compared by Mann Whitney rank sum test. Spearman's rank correlation test was 
used to assess the correlations of plasma chemokine with SLEDAI score. Statistical 
analysis was performed using SPSS statistical software for Windows, version 9.0. 
Probability values (p) < 0.05 were considered as significant. 
5.3 Results 
5.3.1 Characteristics of SLE Patients and Control Subjects 
Nineteen female Chinese SLE patients were recruited at the Rheumatology 
Out-patient Clinic of the Prince of Wales Hospital，Hong Kong. Thirteen female 
healthy Chinese subjects were recruited as controls. Twelve mL of EDTA venous 
peripheral blood were collected from each patient and control subject. The 
characteristics of SLE patients and control subjects were listed in Table 5.1. 
5.3.2 Ex vivo Production of IL-17A from PBMC 
Based on Figure 5.1, IL-23 could significantly induce and augment the release of 
IL-17 from anti-CD3 and anti-CD28 activated PBMC in all SLE patients as compared 
with control subjects (p < 0.05). The numerical data is summarized in Table 5.1. 
5.3.3 Circulating Number of Thl7 Lymphocytes 
As shown in Figure 5.2, the number of circulating IL-17A secreting Thl7 
lymphocytes in SLE patients was significantly higher than that of control subjects 
[median (IQR), SLE: 10 (2-30) vs control: 1 (1-2); p < 0.05]. PMA and ionomycin 
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were commonly used stimulators to activate the expression of IL-17 in Thl7 
lymphocytes according to our previous study [Wong et al.’ 2001]. No Thl7 
lymphocyte was detected by ELISPOT without the stimulation of PMA and 
ionomycin (data not shown). 
Table 5.1 Characteristics of SLE patients and control subjects 
SLE Control 
Number 19 13 
Sex (female/male) 19/0 13/0 
A / � c n � 39.5 士 11 40 士 7 Age, year (mean 士 SD’ range) (2 丨 _ ^^^ ( 2 � _ 56) 
Duration of diagnosis, year, 12.4 士 6.9 ^ . 
Mean 士 SD (range) (1 .3 -29) 
SLEDAI Score 4.2 ±3.1 ^ ^ 
mean 士 SD (range) ( 0 - 1 2 ) 
Treatment with prednisolone 
Patients, no. (%) 18(94.7) 
Daily dose, mg 6.9 ±3.6 NA 
mean 土 SD (range) (2.5 - 17.5) 
Treatment with hydroxychloroquine 
Patients, no. (%) 8 (42 1) 
Daily dose mg 202.5 ± 86.5 NA 
mean ± S D (range) (20-300) 
Treatment with azathioprine 
Patients, no. (%) 7 (36.8) 
Daily dose, mg 60.7 ±19.7 NA 
mean 士 SD (range) (50 - 100) 
Values are in mean 士 SD (range); NA: not applicable 
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Control subjects SLE Patients 
Medium 6.8(5.6-12.3) 6.5 (5.5-10.1) 
IL-23 10.3 (6.2-15) 6.3 (5.6-12.1) 
CD3 15.5(11.6-23.2)++ 6.3 (5.6-12.1) 
CD3+CD28 1 5 . 6 ( 1 1 . 5 - 2 8 . 2 ) ^ 21 ( 1 4 . 8 - 4 0 . 6 ) + 十 + 
IL-23+CD3+ CD28 22 (13.6-46)+++ 30(21.4-61)+++,* 
Table 5.1 Ex vivo production of IL-17A from anti-CD3, anti-CD28 and IL-23 
activated PBMC. Culture supernatant was obtained from PBMC cultured with 
medium with or without anti-CD3 antibody, anti-CD28 antibody (1 |j,g/mL each) and 
IL-23 (50 ng/mL) for 24 h. Data was presented as median (IQR) in pg/mL. Difference 
in the expression of IL-17A was compared with Mann Whitney rank sum test. 
* p < 0.05 by comparison between control subjects and SLE patients. + p < 0.05, ++ p 
< 0.01, +++ p < 0.001 by comparison with medium. CD3 : anti-CD3 antibody, CD28 : 
anti-CD28 antibody. 
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Figure 5.1 Ex vivo production of IL-17A from anti-CD3, anti-CD28 and IL-23 
activated PBMC Culture supernatant was derived from PBMC cultured with 
medium with or without anti-CD3 antibody, anti-CD28 antibody (1 |j.g/mL each) and 
IL-23 (50 ng/mL) for 24 h. Results are presented with Box-and-Whisker plots. 
Difference in the expression of IL-17A before (medium) and after treatment, and the 
expression among SLE patients and control subjects was compared with Mann 
Whitney rank sum test, * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Figure 5.2 IL-17A secreting Thl7 lymphocytes in PBMC of SLE patients and 
control subjects IL-17A secreting Thl 7 lymphocytes upon 24 h activation by PMA 
(50 ng/ml) and ionomycin (1 |ag/ml) in 1x10^ PBMC was assayed by ELISPOT. 
Difference in the number of Thl7 lymphocytes between SLE patients and control 
subjects (CTL) was compared with Mann Whitney rank sum test. Results are 
presented with Box-and-Whisker plots, * p < 0.05. 
5.4 Discussion 
IL-23, a novel cytokine closely resembles IL-12, is a crucial cytokine for Thl7 
development, whereas IL-12 is involved in the production Thl lymphocytes. As 
reported by Dr. Lydia Lit from our group, the plasma level of IL-23, IL-12, IL-17 and 
Thl chemokine CXCLIO was significantly higher in SLE patients than control 
subjects, suggesting that these Thl- and Thl7-related cytokines and chemokines are 
involved in the pathogenesis of SLE [Wong et al., 2008]. To support the observation, 
study by Gocke et al. has also reported that the Thl transcription factor T-bet could 
up-regulate IL-23 receptor expression and the differentiation of Thl and Thl7 
lymphocytes in autoimmunity [Gocke et al., 2007]. Concurrently, previous study by 
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our group also found an up-regulation in mRNA expression of T-bet and Thl cytokine 
IFN-y; with reciprocal suppressed expression of Th2 transcription factor GATA-3 and 
Th2 cytokine IL-4 in SLE patients, suggesting the functional activation of peripheral 
blood Thl lymphocytes in SLE patients [Lit et al., 2007]. 
IL-17 is a pleiotropic inflammatory cytokine which can induce multiple 
cytokines production on various cell types, including epithelial, endothelial and 
fibroblastic cells [Kawaguchi et al., 2004]. IL-17 has been implicated in many chronic 
autoimmune diseases including psoriasis, rheumatoid arthritis and multiple sclerosis 
[Kikly et al” 2006]. As reported by Dr. Lydia Lit, the simultaneous increase in plasma 
concentrations of IL-12, IL-23, and IL-17 with Thl chemokine CXCLIO further 
confirmed the immunopathological role of IL-12 mediated Thl immunity and IL-23 
mediated Thl7 auto-inflammatory processes of SLE, which is further exemplified by 
their positive correlations with disease activity [Wong et al., 2008]. The findings 
supported that the above studied cytokine cascade could play a pathological role in the 
development of auto-inflammatory response in SLE patients, probably through the 
recruitment of the effector leukocytes to the inflamed tissue for coordinating the 
immunoresponse at the site of inflammation. 
For better understanding the involvement of IL-23 in the IL-23/IL-17 
auto-inflammatory axis and the immunopathological mechanisms of the activation of 
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Thl7 lymphocytes in SLE, we have elucidated the effect of IL-23 on the ex vivo 
production of IL-17 from the anti-CD3 and anti-CD28 co-stimulated PBMC. Upon 
IL-23 induction, the costimulated PBMC responded with an aberrant ex vivo 
production of IL-17 and the increase was significantly higher in SLE patients than 
controls (p < 0.05). Based on this result, we can proof the direct involvement of IL-23 
in the IL-23/IL-17 inflammatory axis, which acts to induce the distinct T cell 
population that produces IL-17 as the effector cytokine for promoting the 
autoinflammatory responses in SLE. To further elucidate the immunopathological role 
of Thl 7 in SLE, ELISPOT was employed to assess the presence of circulating Thl7 
lymphocytes in the peripheral blood of SLE patients. Our results revealed that SLE 
patients express significantly higher number of Thl 7 lymphocytes than that in normal 
control subjects. Since ELISPOT assay can detect the IL-17A secreting Thl7 
lymphocytes at the single cell level, thus it could be considered as a more precise and 
sensitive test than conventional ELISA measurement of circulating IL-17 or mRNA 
expression by RT-PCR. 
IL-18 is a potent upstream pro-inflammatory cytokine for the induction of 
chemokines release from activated PBMC. Previous study by our group also revealed 
a significant high expression of plasma IL-18 in SLE patients, which is also positively 
correlated with the SLE disease activity [Wong et al., 2000]. We hypothesized that 
84 
Chapter 5 Th 17 Lymphocytes and Expression of IL-17 in SLE 
IL-18 could able to induce an aberrant release of IL-12, IL-17 and IL-23 from 
activated PBMC, thus contributing to the auto-inflammatory process in SLE 
manifestation. Study by Dr. Lydia Lit has revealed that the ex vivo production of 
IL-12, IL-23 and IL-17 upon anti-CD3 and anti-CD28 antibody activation from 
PBMC was significantly enhanced by the presence of IL-18, and the increases in all 
these cytokines production were significantly higher in all SLE patients [Wong et al., 
2008]. These findings indicated that the expression of inflammatory cytokines IL-12, 
IL-23, IL-17, and activation of Thl7 lymphocytes are in part influenced by 
proinflammatory cytokine IL-18 present in the local environment of the cells at the 
time of stimulation. Taken together with the previous result by our group on the 
association of proinflammatory cytokine IL-18 with SLE disease activity [Wong et al., 
2000], IL-23-mediated activation of Thl 7 lymphocytes in SLE patients may be 
closely influenced by IL-18 activation which orchestrates the inflammation of SLE. 
More recent publications also demonstrated that the development and differentiation 
of human Thl7 lymphocytes from naive T lymphocytes required the activation by 
IL-lp and IL-6 which concurrently associated with the increase of Thl cytokine IL-12 
during inflammation [Acosta-Rodriguez et al., 2007]. The whole panel of cytokines 
secretion and their interaction may be involved in various diseases presentation, and 
further experiments are required for clarifying the complex relationship between the 
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Thl cytokine IL-12 and the Thl7 developments in patients with autoimmune diseases. 
Pharmacological control of the production of IL-12 and IL-23 may constitute a key 
therapeutic strategy in the modulation of specific immune-mediated diseases 
dominated by Thl cytokines and IL-17 responses. In summary, proinflammatory 
cytokine IL-18 and IL-12 family cytokines IL-12 and IL-23 can promote the disease 
severity by activating pathogenic Thl and Thl7 lymphocytes via the induction of 
downstream Thl chemokine CXCLIO and inflammatory cytokine IL-17 in SLE. Our 
results should provide new insights for their potential pathological roles in SLE, and 
shed light on the development of SLE disease markers. The IL-23/IL-17 axis of 
inflammation and related molecules may rise as therapeutic targets for treating 
autoimmune diseases. 
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Intracellular Mitogen Activated Protein Kinases in SLE 
6.1 Introduction 
Mitogen activated protein kinases (MAPKs) are proline-directed serine and 
threonine protein kinases that can be activated in response to extracellular stimuli, 
such as mitogens, growth factors, cytokines and stress. Nuclear translocation of 
activated MAPKs can induce and transactivate transcription factors including 
activator protein 1 (AP-1), which facilitate the modulation of gene transcription in 
cellular activation, proliferation, and the production of cytokines, adhesion molecules, 
and metalloproteinases [Chang et al, 2001]. Three distinct MAPKs, p38 MAPK, 
p42/p44 extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal protein 
kinase (JNK) have been identified in mammalian cells. The p38 MAPK is activated 
by osmotic stress, UV radiation, ionizing radiation, bacterial cell wall product such as 
LPS and various proinflammatory cytokines including TNF-a [Kyriakis et al., 2001]. 
The major function of p38 MAPK is to regulate cellular degranulation, chemotaxis 
and expression of adhesion molecules during inflammation. It also controls cell cycle 
progression, differentiation and apoptosis [Aouadi et al.’ 2006]. 
The ERK pathway acts as central mediator in cell proliferation, transformation 
and differentiation. It can be activated by growth factor like IL-5 [de Groot et al., 
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1998]. During inflammation, ERK activation can promote CXCL8 production from 
neutrophils [Jo et al.，2004]. Inhibition of ERK pathway can also repress lung 
inflammation via suppressing the Th2 cytokines production [Chialda et al., 2005]. 
The JNK pathway is responsible for transduction of cellular stress signals and 
can be potently activated by irradiation, inflammatory cytokines and other 
environmental stresses such as hyperosmolarity [Derijard et al, 1994]. JNK enhances 
the transcriptional activity of activating protein 1 (AP-1) by phosphorylation [Hibi et 
al., 1993]. Binding sites for AP-1 exist in the promoter regions of several cytokine 
genes including those encoding CXCL8 and CCL5 [Mukaida et al.’ 1989; Nelson et 
al., 1993]. 
Previous reports have demonstrated that intracellular signaling molecules such as 
nuclear factor-kappa B (NF-KB) , J N K and p38 M A P K play crucial roles in TNF-a , 
IL-5 and IL-25-mediated signaling pathways, which can regulate the release of 
chemokines and the expression of adhesion molecules of eosinophils [Blasini et al., 
1998; Wong et ai, 1999; Tada et al,, 1991]. In a clinical study of SLE, we have shown 
that aberrant production of soluble T cell costiniulatory molecules should be 
important in the immunopathogenesis of SLE by the dysregulation of T lymphocyte 
costimulation [Wong et al., 2005]. Studies on intracellular signaling molecules in SLE 
indicated that abnormal NF-KB, protein tyrosine kinase, protein kinase A, Src kinases 
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activity and defective protein kinase C in T lymphocytes in SLE patients [Blasini et 
al” 1998; Wong et al” 1999; Tada et al； 1991; Fujii et al., 2006; Kammer, 2002]. 
Another studies showed the B cell kinase deficiency in SLE patients [Liossis et al., 
2001; Jury et al., 2003]. However, the activation of intracellular ERK, JNK and p38 
MAPK for the abnormal effector functions of T lymphocytes, B lymphocytes and 
macrophages and their relationship with the immunopathogenesis in SLE has not been 
elucidated. 
Our previous studies have demonstrated an elevated plasma IL-18 concentration 
is correlated with SLE disease activity and associated with renal disease in patients 
with systemic lupus erythematosus [Wong et al., 2000]. IL-18, an inflammatory 
cytokine, was originally identified as a factor that enhances IFN-y production in 
various cell types, including macrophages, T lymphocytes, B lymphocytes and 
dendritic cells [Dinarello, 1999]. Previous reports have demonstrated the involvement 
of IL-18 in initiating both innate and acquired immune responses [Hoshino et al., 
1999; Yosliimoto et al.’ 2000]. It has been reported that IL-18 along with IL-12 is a 
potent inducer of the inflammatory mediators by T lymphocytes, resulted in severe 
auto-inflammatory response such as rheumatoid arthritis [Dinarello, 1999; Fehniger et 
al” 1999]. 
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To characterize the intracellular activation mechanism in SLE, we have 
investigated the differential expression of phosphorylated ERK, JNK and p38 MAPK 
in leukocyte subsets including CD4+T lymphocytes, CD8+T lymphocytes, CD19+B 
lymphocytes and monocytes. For further understanding the role of IL-18 on MAPK 
activities, phospho-ERX, phospho-JNK and phospho-p38 MAPK in monocytes, 
CD4+T lymphocytes, CD8+T lymphocytes and CD19+B lymphocytes were measured 
upon the ex vivo activation by IL-18. Based on our previous studies of intracellular 
signal transduction mechanisms in inflammation, our hypothesis was that intracellular 
signaling molecules ERK, p38 MAPK and JNK, together with the inflammatory 
cytokine IL-18, form a network in orchestrating auto-inflammatory process in SLE. 
6.2 Methods 
PBMC were purified from SLE patients and control subjects by ficoll gradient 
centrifugation. The expression of phosphorylated MAPK in resting stage (medium, 
3 7 � C for 12 mins) or activated stage IL-18 activated (20 ng/mL, 37�C for 12 mins) 
PBMC was investigated. Fluorochrome conjugated antibodies specific for surface 
markers of Th lymphocyte (CD4+), Tc plus Ts lymphocyte (CD8+) and B lymphocyte 
(CD 19+) were used in combination with antibodies that recognize phosphorylated 
ERK, JNK or p38 MAPK for staining fixed and permeabilized PBMCs (BD 
Biosciences). Peripheral blood monocytes were differentially analyzed by excluding 
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lymphocytes using their forward and side scatter properties. The results were analyzed 
by flow cytometry (BD, FACSCalibur). The differential expression of phosphorylated 
MAPK in monocytes, CD4+T lymphocytes, CD8+T lymphocytes and CD19+B 
lymphocytes was presented as mean fluorescence intensity (MFI). The relative 
percentage increase of phospho-MAPK upon IL-18 stimulation was calculated based 
on the percentage change of phosphorylated MAPK expression before (resting in 
medium) and after IL-18 stimulation. 
Numerical data were expressed as median (interquartile range, IQR) if not in 
Gaussian distribution. Difference in MAPK expressions between SLE and control 
subjects was compared with Mann Whitney rank sum test. Spearman's rank 
correlation test was used to assess the correlations of phosphorylated MAPK 
expression with SLEDAI score. Statistical analysis was performed using SPSS 
statistical software for Windows, version 9.0. Probability values (p) < 0.05 were 
considered as significant. 
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6.3 Results 
6.3.1 Characteristics of SLE Patients and Control Subjects 
Twenty-two Chinese SLE patients were recruited at the Rheumatology 
Out-patient Clinic of the Prince of Wales Hospital, Hong Kong. Twenty healthy 
Chinese volunteers were recruited as controls. Twelve mL of EDTA venous peripheral 
blood were collected from each patient and control subject. The characteristics of SLE 
patients and control subjects were listed in Table 6.1. 
6.3.2 Expression of Phospho-p38 MAPK in PBMC 
As shown in Figure 6.1, the expression of phospho-p38 MAPK at resting stage 
was significantly higher in (B) CD4+T lymphocyes, (C) CD8+T lymphocytes and (D) 
CD19+B lymphocytes of SLE patients than control subjects (all p < 0.05). Upon 
stimulation of IL-18, the expression of phospho-p38 was also elevated in (B) CD4+T 
lymphocytes, (C) CD8+T lymphocytes and (D) CD19+B lymphocytes in SLE patients 
(all p < 0.05). The numerical results are presented in Table 6.2. 
Spearman's rank correlation test was also performed to calculate the possible 
correlation between the phospho-p38 MAPK expression and SLEDAI upon ex vivo 
stimulation of IL-18. From Figure 6.2, (A) CD4+T lymphocyte, (B) CD8+T 
lymphocyte and (C) CD19+B lymphocyte has shown marginal insignificance despite 
relatively high correlation coefficient was observed [CD4+T lymphocyte: r= 0.4, p = 
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0.08; CD8+T lymphocyte: r = 0.41，p = 0.075; CD19+B lymphocyte: r = 0.42, p = 
0.064]. 
6.3.3 Expression of Phospho-ERK in PBMC 
As illustrated in Figure 6.3，no significant difference was observed for the 
expression of phospho-ERK in monocytes and lymphocytes between SLE patients 
and control subjects at resting stage or under IL-18 stimulation. Numerical results are 
reported in Table 6.3. In addition, no correlation between the expression of 
phospho-ERK and SLEDAI was observed (data not shown). 
6.3.4 Expression of Phospho-JNK in PBMC 
Figure 6.4 shows that there was no significant difference in the expression of 
phospho-JNK at resting stage in (B) CD4+T lymphocytes, (C) CD8+T lymphocytes 
and (D) CD19+B lymphocytes between SLE patients and control subjects. However, 
upon ex vivo stimulation of IL-18, the expression of phospho-JNK was remarkably 
elevated in (C) CD8+T lymphocytes and (D) CD19+B lymphocytes in SLE patients 
(all p < 0.05). The numerical results are presented in Table 6.4. 
Spearman's rank correlation test was performed to calculate the correlation 
between the phospho-JNK expression and SLEDAI upon ex vivo stimulation of IL-18. 
As shown in Figure 6.5, (A) CD8+T lymphocyte has shown a significant correlation 
between the expression of phospho-JNK and SLEDAI (r = 0.46, p = 0.044). However, 
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as shown in Figure 6.5，(B) CD19+B lymphocyte has shown marginal insignificance 
despite relatively high correlation coefficient was observed (r = 0.4，p = 0.08). 
6.3.5 Relative Percentage Increase of the Phosphorylated p38 MAPK, ERK and 
JNK upon IL-18 Activation 
There was no significant difference in the relative percentage increase of the 
phosphorylated (A) p38 MAPK, (B) ERK and (C) JNK between SLE patients and 
control subjects upon IL-18 activation (Figure 6.6). The numerical data was presented 
in Table 6.2, 6.3 and 6.4 respectively. However, as shown in Figure 6.7, the relative 
expression of phospho-JNK after IL-18 stimulation was significantly correlated with 
SLEDAI after calculated by Spearman's rank correlation test (r = 0.47, p = 0.049). 
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Table 6.1 Characteristics of SLE patients and control subjects 
SLE Control 
Number 22 20 
Sex (female/male) 22/0 18/2 
A / 丄 cT^ 、 36 士 9 48 士 7 Age, year (mean 士 SD, range) (21.5I) (32 - 58) 
Duration of diagnosis, year, 10.6 土 7.6 
Mean ± SD (range) ( 1 - 3 0 ) 
SLEDAI Score 3.3 ±3.2 
Mean ± SD (range) (1 - 11) 
Treatment with prednisolone 
Patients, no. (%) 21(95.5) 
Daily dose, mg 35 士 107 NA 
Mean 士 SD (range) (5 - 500) 
Treatment with hydroxychloroquine 
Patients, no. (%) 
Daily d o s ^ m g 225 ± 4 6 NA 
Mean ± S D (range) (200-300) 
Treatment with azatliioprine 
Patients, no. (%) 6 (27) 
Daily dose, mg 70.8 士 33.2 NA 
Mean 士 SD (range) (25 - 100) 
Values are in mean 士 SD (range); NA: not applicable 
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Cell type Group Rest in medium Activated by Relative % increase 
IL-18 after IL-18 activation 
Monocytes CTL 53 (43-106) 62 (48-114) 9 (0-46) 
SLE 103 (58-201) 128 (68-233) 11(0-27) 
CD4+T CTL 18 (11-60) 28 (17-92) 34 (0-138) 
cells SLE 42 (28-124)* 58 (31-150f 52(10-112) 
CD8+T CTL 12 (6-17) 15 (10-42) 50 (5.6-117) 
cells SLE 31 (14-116)** 54 (19-98/ 23 (0-67) 
CD19+B CTL 12 (8-26) 21 (9-56) 25 (3.4-165) 
cells SLE 36 (15-146)* 49 (25-166f 33 (0-114) 
Table 6.2 Expression of phospho-p38 MAPK in resting or IL-18 stimulated 
PBMC PBMC (1x10^ cells/mL) was stimulated by IL-18 (20 ng/mL) or rested in 
medium for 12 mins at 37°C. The differential expression of monocytes and 
lymphocyte subsets was analyzed by flow cytometry as MFI in 5000 viable cells. 
Numerical data were expressed as median (IQR). Mann Whitney rank sum test was 
used to assess the differences of phospho-p38 MAPK expression among SLE patients 
and control subjects (CTL) in resting (*p < 0.05, **p < 0.01)，upon IL-18 activation 
(#p < 0.05) and the relative percentage increase of phospho-p38 MAPK after IL-18 
activation. 
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Figure 6.1 Expression of phospho-p38 MAPK in resting or IL-18 activated 
PBMC. PBMC (1x106 cells/mL) was stimulated by IL-18 (20 iig/mL) or rested in 
medium for 12 mins at 37"C. The differential expression of phospho-p38 MAPK in 
(A) monocytes, (B) CD4+T lymphocytes, (C) CD8+T lymphocytes and (D) CD19+B 
lymphocytes was analyzed by flow cytometry as MFI in 5000 viable cells. Mann 
Whitney rank sum test was used to assess the differences of phospho-p38 MAPK 
expression among SLE patients and control subjects (CTL). Results are presented 
with Box-and-Whisker plots, * p < 0.05, **p < 0.01. 
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Figure 6.2 Correlation between phospho-p38 MAPK expression and SLE 
disease activity in IL-18 activated PBMC. Spearman's rank correlation test was 
performed to calculate the correlation between phospho-p38 MAPK expression and 
SLEDAI ill (A) CD4+T lymphocytes, (B) CD8+T lymphocytes and (C) CD19+B 
lymphocytes in IL-18 activated PBMC. Results are presented as scatter plot. 
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Cell type Group Rest in medium Activated by Relative Vo 
IL-18 increase after 
IL-18 activation 
Monocytes CTL 82 (59-144) 90 (57-177) 0 (0-1) 
SLE 87 (32-200) 86 (54-173) 3.1 (0-21.3) 
CD4+T CTL 43 (32-62) 47 (36-70) 0 (0-56.6) 
cells SLE 47 (32-96) 60 (42-143) 13.9 (0-51.8) 
CD8+T CTL 35 (20-64) 39 (22-79) 0 (0-26) 
cells SLE 57 (18-110) 64 (29-106) 8.9 (0-32.1) 
CD19+B CTL 41 (19-66) 42 (25-93) 5 (0-46.5) 
cells SLE 54(18-150) 61 (30-160) 20.7 (0-63.9) 
Table 6.3 Expression of phospho-ERK in resting or IL-18 stimulated PBMC 
PBMC (1x10^ cells/mL) was stimulated by IL-18 (20 ng/mL) or rested in medium for 
12 mins at 37°C. The differential expression of monocytes and lymphocyte subsets 
was analyzed by flow cytometry as MFI in 5000 viable cells. Numerical data were 
expressed as median (IQR). Mann Whitney rank sum test was used to assess the 
differences of phospho-ERK expression between SLE patients and control subjects 
(CTL) in resting, upon IL-18 activation and the relative change of phospho-ERK 
expression after IL-18 activation. 
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Figure 6.3 Expression of phospho-ERK in resting or IL-18 activated PBMC. 
PBMC (lxl06 cells/mL) was stimulated by IL-18 (20 ng/mL) or rested in medium for 
12 mins at 37"C. The differential expression of phospho-ERK in (A) monocytes, (B) 
CD4+T lymphocytes, (C) CD8+T lymphocytes and (D) CD19+B lymphocytes was 
analyzed by flow cytometry as MFI in 5000 viable cells. Mann Whitney rank sum test 
was used to assess the differences of phospho-ERK expression among SLE patients 
and control subjects (CTL). Results are presented with Box-and-Whisker plots. 
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Cell type Group Resting in Activated by Relative % 
medium IL-18 increase after 
IL-18 activation 
Monocyte CTL 92 (71-223) 94 (72-250) 0 (0-17.1) 
SLE 164 (77-250) 172 (88-247) 6.2 (0-17.7) 
CD4+T CTL 26 (19-37) 31 (23-45) 22.8 (0-59.2) 
cells SLE 30 (20-68) 40 (20-125) 40.9 (8.4-118) 
CD8+T CTL 25 (19-64) 27(18-63) 6.9(0-21.7) 
cells SLE 40 (24-102) 60 (32-125/ 2 (0-75.5) 
CD19+B CTL 31 (19-51) 32 (23-72) 1.8 (0-27.1) 
cells ^ 77 (26-127) 88 (31-185)# 5.1 (0-80.7) 
Table 6.4 Expression of phospho-JNK in resting or IL-18 stimulated PBMC 
PBMC ( 1 x 1 c e l l s / m L ) was stimulated by IL-18 (20 ng/mL) or rested in medium for 
12 mins at 37°C. The differential expression of monocytes and lymphocyte subsets 
was analyzed by flow cytometry as MFI in 5000 viable cells. Numerical data were 
expressed as median (IQR). Mann Whitney rank sum test was used to assess the 
differences of phospho-JNK expression among SLE patients and control subjects 
(CTL) in resting, upon IL-18 activation (#p < 0.05) and the relative change of 
phospho-JNK expression after IL-18 activation. 
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Figure 6.4 Expression of phospho-JNK in resting or IL-18 activated PBMC. 
PBMC (1x10^ cells/mL) was stimulated by IL-18 (20 ng/mL) or rested in medium for 
12 mins at C. The differential expression of phospho-JNK in (A) monocytes, (B) 
CD4+T lymphocytes, (C) CD8+T lymphocytes and (D) CD19+B lymphocytes was 
analyzed by flow cytometry as MFI in 5000 viable cells. Mann Whitney rank sum test 
was used to assess the differences of phospho-JNK expression among SLE patients 
and control subjects (CTL). Results are presented with Box-and-Whisker plots, * p < 
0.05. 
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Figure 6.5 Correlation between phospho-JNK expression and SLE disease 
activity in IL-18 activated PBMC. Spearman's rank correlation test was 
performed to calculate the correlation between phospho-JNK expression and SLEDAI 
in (A) CD8+T lymphocytes and (B) CD19+B lymphocytes in IL-18 activated PBMC. 
Results are presented as scatter plot. 
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Figure 6.6 Relative percentage increase of the phosphorylated p38 MAPK, 
ERK and JNK in IL-18 activated PBMC. The percentage change of (A) 
phospho-p38 MAPK, (B) phospho-ERK and (C) phospho-JNK expression before and 
after IL-18 stimulation was presented in Box-and-Whisker plots. Mann Whitney rank 
sum test was used to assess the differences of relative change among SLE patients and 
control subjects (CTL). 
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Figure 6.7 Correlation between the relative change of phospho-JNK and SLE 
disease activity. Spearman's rank correlation test was performed to calculate the 
correlation between the relative change of phospho-JNK expression upon IL-18 
stimulation and SLEDAI. Results are presented as scatter plot. 
6.4 Discussion 
SLE is a chronic autoimmune disorder characterized by lymphocytes 
abnormalities and autoantibody production. Previous studies by our group have 
demonstrated that intracellular MAPK can regulate the activation of eosinophils and 
memory T lymphocytes in chronic inflammatory diseases [Wong et al, 2004; Wong et 
al., 2007]. Therefore we hypothesized that abnormal activation of intracellular MAPK 
may account for the activation of B lymphocytes, T lymphocytes and monocytes and 
the subsequent aberrant induction of Thl/Th2 cytokines and chemokines, and hence 
the exacerbation of SLE. Analysis of signal transduction in rare subpopulation of the 
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peripheral blood cells has been challenging because of the large number of cells 
needed for conventional biochemical assessment. Therefore, we though that it would 
be fruitful to base on our well-established intracellular staining with subsequent flow 
cytometric analysis of signaling molecules to elucidate the intracellular MAPK 
cascades for the activation of different leukocyte subsets including CD4+T 
lymphocytes, CD8+T lymphocytes, CD19+B lymphocytes and monocytes in SLE. 
Our results demonstrated that the basal expressions (rest in medium) of 
phospho-p38 MAPK were significantly increased in B and T lymphocytes of SLE 
patients than control subjects (Figure 6.1)，but the expression is not significantly 
correlated with disease activity (data not shown). During inflammation, p38 MAPK is 
activated in various cell types, hence is closely related to apoptosis, stress responses, 
and inflammation [Wang et al., 1997]. In addition, the phosphorylation of p38 MAPK 
participates in the production of inflammatory cytokines and chemokines including 
CCL2, IL-lp, and TNF-a, in human mesangial cells [Rovin et al., 1999] and human 
endothelial cells [Goebeler et al., 1999]. Based on the results, we questioned that 
elevated activation of intracellular p38 MAPK signaling pathways in SLE patients 
may cause lymphocytes hyperactivity, which resulted in aberrant expressions of 
cytokines and chemokines for triggering the subsequent inflammatory processes in 
SLE patients. Apart from the p38 MAPK signaling pathway, we also found out that 
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the expressions of phospho-JNK were significantly elevated in B and T lymphocytes 
of SLE patients upon the ex vivo activation of IL-18 (Figure 6.4). In addition, the 
expression of phospho-JNK in IL-18 activated CD8+T lymphocyte is significantly 
correlated with disease activity (Figure 6.5). Notably, the relative change of 
phospho-JNK expression upon IL-18 activation is also closely related with disease 
activity in CD19+B lymphocytes (Figure 6.7). However, in resting or IL-18 activated 
monocytes, the expression of phospho-p38 MAPK and JNK among SLE patients and 
control subjects did not reflect significantly change (Figure 6.1 and 6.4), and the 
correlation with disease activity is not significant (data not shown). Therefore, we 
hypothesized that elevated expression of phosphorylated JNK and p38 MAPK in SLE 
patients may result in B and T lymphocyte hyperactivity for the exacerbation of SLE 
pathology. In support of this hypothesis, Grammer et al. reported that significantly 
higher percentage of phosphorylated ERK, JNK and p38 MAPK in CD 19+ B 
lymphocytes was observed in active SLE patients than normal control individuals 
[Grammer et al” 2004]. However, some studies demonstrated that phospho-ERK was 
decreased in active SLE, and inhibition of T cell ERK signaling pathway can decrease 
DNA methyl transferase (DNMT) expression and induce autoimmunity [Deng et al., 
2001; Deng et al., 2003]. In contrast, our results revealed that no significant 
difference was observed for the phosphorylation of ERK in resting or IL-18 activation 
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monocyte, T and B lymphocytes among SLE patients and control subject (Figure 6.3). 
Indeed, the discrepancies as reported by these studies might largely be explained by 
the use of different choice of antibodies and biochemical assessment for signaling 
stage. Instead of the conventional Western blot analysis, we quantitated the 
intracellular MAPK activity by flow cytometry, so that the phosphorylation stage of 
different lymphocyte subpopulations can be analyzed. Indeed, ERK is mainly 
activated by growth factor while JNK and p38 MAPK are more responsive to 
inflammatory cytokine. Therefore, we can see a significantly elevation of the 
phosphorylated p38 MAPK and JNK instead of the ERK. In fact, various studies have 
revealed that the JNK and p38 MAPK hyperactivity is closely related to 
autoimmunity. For example, Iwata et al. detected reduced serum levels of 
immunoglobulin (Ig) and anti-dsDNA antibodies and decreased deposition of Ig in the 
kidney by inhibition of p38 MAPK [Iwata et al., 2003]. Supporting these evidences, a 
recent study revealed that p38 MAPK activation is crucial for B cell activation 
leading to Ig production [Bishop et aL, 2000], and p38 MAPK also regulates the 
production of a number of cytokines, including IL-6 that promotes differentiation and 
survival of plasma cells. Study by Yoshimoto et al. also reported that B cell-activating 
factor of the TNF family (BAFF)，which is essential for B cells activation and 
differentiation, was regulated through JNK and p38 MAPK [Yoshimoto et aL, 2006]. 
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In addition, nuclear factor of activated T cells (NFAT), which are transcription factors 
located downstream of the ERK and JNK pathways, are essential for T lymphocyte 
and B lymphocyte activation and differentiation [Peng et al., 2001]. Specific 
anti-NFAT drug therapy has shown to be pharmacologic armamentarium against 
rheumatoid arthritis, inflammatory arthropathies, and related autoimmune disorders. 
Collectively, these data support our results that JNK and p38 MAPK are the key 
mediators in regulating the activity of T and B lymphocytes. Thus we suggest that 
JNK and p38 MAPK may be an appealing therapeutic target for combating in 
autoimmune diseases. 
Numerous studies have demonstrated that inhibition of the JNK and p38 MAPK 
pathway has profound effects on inflammatory cytokine synthesis and modulation of 
acute and chronic inflammation [Adams et al., 2001]. For example, significant effects 
have been observed in murine models of pulmonary inflammation [Nick et al., 2000], 
CIA, and adjuvant-induced arthritis [Badger et al., 1996] by treating with potent, 
selective p38 inhibitors. Suppression of JNK pathway is involved in the inhibition of 
inflammatory target gene expression [Park et al., 2008]. These studies have further 
support that inhibition of the JNK and p38 MAPK signaling pathways will have a 
promising future for the therapeutic target in SLE. 
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Apart from the MAPK signaling pathway, nuclear factor kappa B (NF-KB) also 
play important role in SLE pathogenesis. NF-KB is a transcription factor that present 
in cells as inactive state and do not require new protein synthesis to be activated. It is, 
therefore, a first responder to harmful cellular stimuli such as stress, cytokines, free 
radicals, ultraviolet irradiation, bacterial or viral antigens [Gilmore, 1999]. NF-KB has 
been associated with cancer, viral infection, inflammatory and autoimmune diseases. 
Study by Blasini et al. also reported that abnormal NF-KB activity in T lymphocytes 
in SLE patients [Blasini et al., 1998]. The action of NF-kB is counteracted by its 
inhibitory protein IKB, which can mask the nuclear localization signals of NF-KB and 
keep them in an inactive state in the cytoplasm [Jacobs et al., 1998]. IKB is, therefore, 
regarded as a key modulator of the immune responses. However, the role of IKB in 
SLE has not been fully elucidated. To further understand the intracellular signaling 
pathway of IKB in SLE, we will perform a follow-up experiment on the differential 
expression of phosphorylated IKB in CD4+T lymphocytes，CD8+T lymphocytes, 
CD 19+B lymphocytes and monocytes in SLE patients. This study may further support 
the aberrant intracellular signaling pathways in SLE and shed light in the development 
of therapeutic target for treating autoimmune diseases. 
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Chapter 7 
Toll-Like Receptors in SLE 
7.1 Introduction 
Toll-like receptors (TLRs) are pattern associated receptors which play essential 
role in innate immunity. They recognize structurally conserved pathogen-associated 
molecular patterns (PAMPs) for triggering intracellular NF-kB, p38 MAPKs, JNK and 
interferon pathway, which results in translocation of transcription factors, cytokine 
modulation, and IFN stimulated gene regulation leading to inflammatory responses 
[Yamamoto et al.，2003]. A number of adaptor molecules are involved in the TLR 
signaling pathway, including myeloid differentiation primary response gene 88 
(MyD88), TIR domain containing adaptor protein (TIRAP), TIR domain-containing 
adapter inducing interferon (TRIP) and TRIF-related adaptor molecule (TRAM). A 
total of 11 TLRs have been discovered in human, in which functions of TLRl to 9 
have been identified. TLRs can be classified into 2 groups according to their cellular 
compartmentalization. The cell surface TLRs (TLRl, 2，4, 5 and 6) are designed for 
the engagement of extracellular pathogens, whereas the intracellular TLRs at 
cytoplasmic compartment (TLR3, 7， 8 and 9) are against intracellular 
pathogen-derived products [Takeda et al., 2003]. 
Increasing evidences shown that TLR stimulation contribute to autoimmune 
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responses. Endosomal TLRs (TLR3, 8 and 9) have been shown to recognize nucleic 
acids such as dsRNA, ssRNA (TLR7 in mice) and unmethylated CpG DNA, 
respectively [Takeda et al., 2003]. 
In addition to their roles in innate immunity, TLRs also participate in the 
development of adaptive immune response. For example, TLR9 is involved in class 
switching to pathogenic autoantibody production in SLE [Ehlers et al. 2006]. In 
addition, TLRs can participate in B cell differentiation and immunoglobulin 
production in T cell independent manner [Poeck et al. 2004; Heit et al. 2004]. Various 
reports have suggested the differential roles of TLRs in Thl/Th2 response. For 
example, TLR4 and 9 are found to instigate Thl responses, while TLR2 and 5 are 
related to the development of Th2-related immunity [Schnare et al. 2001; Redecke et 
al. 2004; Didierlaurent et al 2004]. 
Several studies have reported the roles of TLR in autoimmunity. Christensen et 
al. has demonstrated that the opposite roles of TLR7 and TLR9 in SLE. Their findings 
suggested that lupus-prone mice deficient in TLR7 failed to generate antibodies 
against RNA-containing antigens such as Smith (Sm), which decreased lymphocyte 
activation and serum IgG. On the other hand, the absence of TLR9 can exacerbate the 
disease activity by the activation of lymphocytes and plasmacytoid dendritic cells 
(pDCs), hence the subsequent increase of serum IgG and IFN-a [Christensen et al., 
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2006]. However, study by Papadimitraki et al. also reported that patients with active 
SLE have increased expression of TLR9 in peripheral blood memory B lymphocytes 
and plasma B lymphocytes, suggesting that endogenous nucleic acids released during 
cell apoptosis may stimulate B lymphocytes via TLR9 and contribute to SLE 
pathogenesis [Papadimitraki et al., 2006]. In order to further study the involvement of 
TLRs in SLE pathogenesis, we have investigated the differential expression profile of 
TLRl to TLR9 of monocyte and lymphocyte subset such as CD4+ Th lymphocytes, 
CD8+ Tc plus Ts lymphocytes and CD 19+ B lymphocytes in SLE patients. In addition, 
we have studied the correlation between TLR expression and SLE disease activity. 
The investigation of TLR expression in SLE patients may provide a useful platform 
for studying the role of TLR in the manifestation of autoimmune diseases, and also 
shed light for the development of novel therapeutic drug against SLE. 
7.2 Methods 
PBMC from SLE patients and control subjects were purified by ficoll gradient 
centrifugation. The expression of TLRl to TLR9 of PBMC of SLE patients and 
control subjects was then investigated by flow cytometry. Fluoroclirome conjugated 
antibodies specific for surface markers of Th lymphocytes (CD4+), Tc plus Ts 
lymphocytes (CD8+) and B lymphocytes (CD 19+) were used in combination with 
antibodies that recognize TLRl to TLR9. Peripheral blood monocytes were analyzed 
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by excluding lymphocytes using their forward and side scatter properties. The 
differential expressions ofTLRl to TLR9 of monocytes, CD4+ T lymphocytes, CD8+ 
T lymphocytes and CD 19+ B lymphocytes were analyzed by flow cytometry (BD, 
FACSCalibur). A total of 5000 events were collected and results were expressed as 
percentage increase comparing with the isotypic control. 
We have also studied the expression of inflammatory cytokines and chemokines 
upon TLR ligand activation. PBMC were incubated with medium and different TLR 
ligands for 24 h at 37 °C in 5% CO2 atmosphere. Ultra-purified lipopolysaccarides 
(LPS), l-(2-methyl propyl)-lH-imidazo[4,5-c]quinolin 4-amine (R837), ssRNA and 
cytosine-phosphate-guanine (CpG) DNA are ligands for human TLR4, 7，8 and 9 
respectively (InvivoGen). Flagellin, double stranded polyinosinic-polycytidylic acid 
(poly IC) and peptidoglycan (PGN), which are specific ligands for TLR5, TLR3 and 
TLR2, respectively, were purchased from Calbiochem, Sigma and Fluka Chemie. 
TLRl and TLR6, which form heterodimer with TLR2, also bind with PGN. The 
inflammatory cytokines including IL-lp, TNF-a, IL-12p70, IL-6 and IL-10 and 
chemokines including CXCL8, CCL5, CXCL9, CCL2 and CXCLIO, were 
simultaneously measured with Human Inflammation CBA Kit and Human Chemokine 
CBA Kit I respectively (BD Phamiingen) using flow cytometry (FACSCalibur, BD 
Biosciences). The relative percentage expression of cytokines and chemokines was 
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calculated based on the percentage difference of expression in medium and after TLR 
ligand stimulation. 
Numerical data were expressed as median (interquartile range, IQR) if not in 
Gaussian distribution. The expression of TLRl to TLR9, and the induction of 
cytokines and chemokines upon TLR ligand activation among SLE patients and 
control subjects were compared with Mann Whitney rank sum test. Spearman's rank 
correlation test was used to assess the correlation between TLR expression and SLE 
disease activity. Statistical analysis was performed using SPSS statistical software for 
Windows, version 9.0. Probability values {p) < 0.05 were considered as significant. 
7.3 Results 
7.3.1 Characteristics of SLE Patients and Control Subjects 
Sixteen Chinese SLE patients were recruited at the Rheumatology Out-Patient 
Clinic of the Prince of Wales Hospital, Hong Kong. Fourteen healthy Chinese 
volunteers were recruited as controls. Twelve mL of EDTA venous peripheral blood 
were collected from each patient and control subject. The characteristics of SLE 
patients and control subjects were listed in Table 7.1. 
7.3.2 Expression of TLRl to TLR9 of PBMC 
As shown in Figure 7.1, the expression of TLRl to TLR6 was significantly 
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higher in monocytes, CD4+ T lymphocytes, CD8+ T lymphocytes and CD 19+ B 
lymphocytes of SLE patients than control subjects (all p < 0.05). Figure 7.2 shows 
that the expression of TLR8 and TLR9 was also up-regulated in monocytes, CD4+ T 
lymphocytes, CD8+ T lymphocytes and CD 19+ B lymphocytes in SLE patients (all p 
< 0.001). TLR7 expressions were not significantly different between SLE patients and 
control subjects (Figure 7.2A). The numerical results of TLR expression are presented 
in Table 7.2. 
Spearman's rank correlation test was performed to calculate the correlation 
between TLR expression with disease activity. As shown in Table 7.3, TLR4 
expression was closely related with SLEDAI score in CD4+ T lymphocytes and 
CD8+ T lymphocytes. The TLR6 expression in CD 19+ B lymphocytes was also 
correlated with disease activity. 
7.3.3. Preliminary Results of Cytokine and Chemokine Expression Upon TLR 
Lignad Activation 
The basal and relative expression of cytokine including IL-12, TNF-a, IL-10, 
IL-1 (3 and IL-6 are summarized in Table 7.4 and 7.5. As for chemokines such as 
CCL2, CCL5, CXCL8 and CXCLIO, the numerical data are presented in Table 7.6 
and 7.7. From the results, no significant difference was observed among SLE patients 
and control subjects. 
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Table 7.1 Characteristics of SLE patients and control subjects 
SLE Control 
Number 16 14 
Sex (female/male) 16/0 12/2 
A / 、 37 士 8 46 ± 1 2 Age, year (mean 士 SD，range) ⑵川 (23 — 58) 
Duration of diagnosis, year, 10.9 士 8.80 ^ . 
Mean 土 SD (range) ( 1 - 3 0 ) 
SLEDAI Score 3.13 士 2.99 . . . NA 
Mean 土 SD (range) (0 - 9) 
Treatment with prednisolone 
Patients, no. (%) 15 (93.8) 
Daily dose, mg 44.1 ±126 NA 
Mean 土 SD (range) (5 - 500) Treatment with hydroxychloroquine Patients, no. (%) 
？产二 � 200 ± 0 NA Mean ± S D (range) (200-200) 
Treatment with azatliioprine 
Patients, no. (%) 5(31.3) 
Daily dose, mg 60.0 士 37.9 NA 
Mean 土 SD (range) (25 - 100) 
Values are in mean 士 SD (range); NA: not applicable. 
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TLRl TLR2 TLR3 
Monocytes CTL 2.40(1.00-9.70) 140(124-196) 108 (87.7-408) 
SLE 0.90 (0.00-11.5) 1830(1560-2330)*** 735 (265-1960)* 
CD4+ CTL 5.90 (3.80-13.1) 3.80 (0.60-30.4) 14.8(12.1-92.5) 
T cells SLE 56.6(13.0-147)*** 58.9(25.2-387)* 190 (78.4-435)*** 
CD8+ CTL 8.60 (7.60-20.0) 1.10(0.70-2.00) 12.3 (8.80-83.9) 
T cells SLE 154 (64.4-243)*** 33.5 (25.6-48.7)*** 160(64.1-399)*** 
CD19+ CTL 0.01 (0.00-42.7) 8.80 (5.90-16.6) 14.5 (10.6-84.9) 
B cells SLE 0.00 (0.00-39.3) 164(138-217)*** 85.0 (53.4-245)** 
TLR4 TLRS TLR6 
Monocytes CTL 19.7(16.2-29.4) 25.4 (23.3-31.0) 18.3 (13.6-25.5) 
SLE 590 (480-923)*** 308 (242-439)*** 339 (248-466)*** 
CD4+ CTL 1.0(0.330-2.69) 1.52(1.01-3.89) 1.06 (0.775-2.63) 
T cells SLE 154(42.4-274)** 83.4 (30.1-188)*** 78.8 (34.3-243)*** 
CD8+ CTL 0.12(0.0-0.18) 1.04 (0.90-1.38) 0.27 (0.190-0.575) 
T cells SLE 13.6(3.62-40.8)*** 29.6(25.7-43.8)*** 13.8 (6.09-26.8)*** 
CD 19+ CTL 1.8 (1.13-4.06) 2.27 (1.68-3.35) 1.89 (1.31-2.88) 
B cells SLE 109(50.4-423)*** 50.7(40.8-74.2)*** 52.1 (30.4-101)*** 
TLR7 TLRS TLR9 
Monocytes CTL 6.18(0.0-16.7) 2690 (2234-4460) 4202 (3500-7090) 
SLE 2.49 (0.0-15.9) 10900(7487-12800)*** 18170(15460-20380)*** 
CD4+ CTL 3.44 (0.0-16.9) 586 (312-1160) 1469(1040-4060) 
T cells SLE 1.76 (0.0-15.9) 3080 (2440-6550)*** 10340 (7750-20130)*** 
CD8+ CTL 5.89 (0.0-25.3) 655 (341-1030) 1390(1160-3610) 
T cells SLE 0.0(0.0-16.2) 4190 (3060-6210)*** 11580(10010-14120)*** 
CD19+ CTL 2.37 (0.0-19.9) 691 (391-1100) 1250(1090-3210) 
B cells SLE 0.0 (0.0-17.1) 3330(2160-4510)*** 9080 (6850-12230)*** 
Table 7.2 Expression of TLRl to TLR9 in SLE patients and control subjects. 
The differential expression of TLRl to TLR9 in monocytes, CD4+ T lymphocytes, 
CD8+ T lymphocytes and CD 19+ B lymphocytes are analyzed by flow cytometry. 
Numerical data are expressed as median (IQR). Maim Whitney rank sum test was 
used to assess the differences of expression among SLE patients and control subjects 
(CTL), * p < 0.05, **p < 0.01，***p < 0.001. 
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Correlation with SLEDAI 
TLRl TLR2 TLR3 
Monocytes r = 0.321, p = 0.244 r = 0.266, p = 0.338 r = 0.063，p = 0.823 
CD4+T cells r = 0.139，p = 0.620 r = 0.472, p = 0.075 r =-0.226, p = 0.417 
CD8+ T cells r = 0.056, p = 0.843 r = 0.076, p = 0.788 r =-0.136’ p = 0.63 
CD19+B cells r = 0.139，p = 0.621 r = 0.205, p = 0.465 r =-0.25, p = 0.388 
TLR4 TLRS TLR6 
Monocytes r = 0.375, p = 0.169 r = 0.091, p = 0.748 r = 0.469，p = 0.078 
CD4+ T cells r = 0.536, p = 0.04 * r = 0.311, p = 0.259 r = 0.375, p = 0.169 
CD8+ T cells r = 0.713, p = 0.003 ** r = 0.022, p = 0.939 r = 0.436, p = 0.104 
CD19+B cells r = 0.478, p = 0.072 r = 0.201, p = 0.473 r = 0.572’ p = 0.026 * 
TLR7 TLRS TLR9 
Monocytes r =-0.368, p = 0.177 r = 0.404, p = 0.136 r = 0.163, p = 0.562 
CD4+ T cells r =-0.437, p = 0.103 r =-0.337, p = 0.22 r = 0.058, p = 0.838 
CD8+ T cells r =-0.394, p = 0.147 r = -0.205, p = 0.465 r =-0.06’ p 二 0.833 
CD19+B cells r =-0.501, p = 0.057 r =-0.42, p = 0.119 r =-0.089, p = 0.753 
Table 7.3 Correlation between TLR expression and SLEDAI score. 
Spearman's rank correlation test was used to assess the correlation between TLR 
expression and SLEDAI score, r = Spearman's correlation coefficient, * p < 0.05, **p 
<0.01. 
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Figure 7.1 Expression of TLRl to TLR6 in SLE patients and control subjects. 
The differential expressions of (A) TLRl, (B) TLR2, (C) TLR3，(D) TLR4, (E) TLRS 
and (F) TLR6 in monocytes (MC), CD4+ T lymphocytes, CD8+ T lymphocytes and 
CD 19+ B lymphocytes were analyzed by flow cytometry. Mann Whitney rank sum 
test was used to assess the differences of expression among SLE patients and control 
subjects (CTL). Results are presented with Box-and-Whisker plots, * p < 0.05, **p < 
0.01, ***p< 0.001. 
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Figure 7.2 Expression of TLR7 to TLR9 in SLE patients and control subjects. 
The differential expressions of (A) TLR7, (B) TLRS and (C) TLR9 in monocytes 
(MC), CD4+ T lymphocytes, CD8+ T lymphocytes and CD19+ B lymphocytes were 
analyzed by flow cytometry. Mann Whitney rank sum test was used to assess the 
differences of expression among SLE patients and control subjects (CTL). Results are 
presented with Box-and-Whisker plots, * p < 0.05, **p < 0.01, ***p < 0.001. 
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CTL SLE CTL SLE 
Basal expression of IL-12 (pg/niL) Relative expression of IL-12 (%) 
Medium 1.00 (0.95-1.25) 1.20 (0.95-1.60) 0 0 
PGN 1.00 (0.85-1.20) 1.15 (0.90-1.45) 18.1 (-20.6-60.0) 16.7 (-22.2-35.5) 
LPS 1.45 (1.35-1.55) 1.20 (0.90-1.65) -9.50 (-36.3-28.0) 40.2 (-0.350-88.9) 
Poly IC 1.10(0.85-1.40) 1.25 (0.90-1.50) 2.40 (-6.10-55.2) 17.6 (-10.0-60.6) 
ssRNA 1.25 (0.95-1.80) 1.35 (1.05-1.55) 36.3 (7.35-66.2) 7.10 (-11.2-52.2) 
Flagellin 1.55 (1.05-1.80) 1.10(0.95-1.30) -0.450 (-7.35-48.2) 4.15 (-21.9-36.4) 
R837 1.15 (0.90-1.45) 1.20 (0.90-1.75) -5.40 (-28.7-11.7) 57.2 (-0.250-82.3) 
CpG 0.95 (0.90-1.30) 0.90 (0.90-1.20) -13.4 (-29.9-13.8) -9.25 (-29.5-78.5) 
Basal expression of TNF-a (pg/mL) Relative expression of TNF-a (%) 
Medium 15.7(2.70-32.7) 11.4 (2.40-21.0) 0 0 
PGN 89.6 (55.7-162) 43.3 (29.4-126) 1020(169-3260) 836(188-2220) 
LPS 232 (178-290) 276 (161-360) 1080(762-10000) 314(1240-10100) 
Poly IC 7.05 (1.95-28.7) 6.55 (2.00-24.2) -9.95 (-63.9-52.6) -15.7 (-44.1-62.3) 
ssRNA 11.4 (2.70-22.4) 6.25 (2.85-25.9) 6.40 (-54.3-76.5) 5.05 (-68.2-76.0) 
Flagellin 160 (72.3-196) 84.5 (60.5-137) 838 (300-3760) 886 (333-3540) 
R837 26.4 (5.75-57.9) 14.5 (3.75-39.2) 66.8 (-22.4-421) 86.1 (-25.1-175) 
CpG 41.9 (3.20-80.5) 15.2 (2.95-24.1) 38.0 (-30.0-728) 22.6 (-40.8-216) 
Basal expression of IL-10 (pg/mL) Relative expression of IL-10 (%) 
Medium 5.25 (3.20-64.8) 5.8 (2.85-133) 0 0 
PGN 64.6 (42.5-108) 79.7(43.2-133) 2060 (470-3620) 1220(455-4840) 
LPS 丨 88 (108-292) 251 (194-617) 3590(1860-5750) 5430 (3200-9490) 
Poly IC 6.00(1.60-20.4) 6.20 (3.30-20.5) -3.70 (-11.2-62.3) 43.9 (-5.40-73.5) 
ssRNA 5.85 (3.65-20.7) 5.30(2.80-21.6) -9.30 (-22.6-160) 10.9 (-6.00-137) 
Flagellin 77.2 (52.3-216) 129 (102-195) 1110(893-3260) 2690(1620-3960) 
R837 19.5 (4.40-98.5) 8.35 (4.40-73.0) 254 (64.6-1930) 174(42.1-657) 
CpG 22.6 (4.25-55.3) 5.75 (2.75-38.6) 47.8 (-6.25-1190) 28.5 (13.7-97.2) 
Table 7.4 Expression of IL-12, TNF-a and IL-10 upon TLR ligand activation. 
Culture supernatant was obtained from PBMC cultured with medium and TLR ligands 
for 24 h. The basal and relative expression ofIL-12, TNF-a and IL-10 by PBMC was 
analyzed by flow cytometry. Numerical data are expressed as median (IQR). Mann 
Whitney rank sum test was used to assess the differences of expression among SLE 
patients and control subjects (CTL). 
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CTL SLE CTL SLE 
Basal expression of IL-1 p (pg/mL) Relative expression of IL-1 P (%) 
Medium 15.0 (5.95-313) 8.65 (3.45-341) 0 0 
PGN 91.9 (64.0-387) 84.8 (39.2-248) 2540 (847-4790) 1160 (560-3110) 
LPS 1500 1870 18200 30600 
(1270-2960) (1170-2450) (10600-59400) (15500-52200) 
Poly IC 11.4(1.60-36.6) 8.55 (3.55-14.9) 0.50 (-28.1-1430) 20.8 (-27.1-121) 
ssRNA 22.8 (8.15-38.8) 8.20 (2.30-44.3) -12.6 (-21.1-1510) 39.0 (-11.4-432) 
Flagellin 687 (449-1140) 305 (198-573) 3850 7910 
(2630-43800) (2380-10720) 
R837 30.5 (17.1-199) 24.8(10.3-64.0) 73.1 (60.8-8260) 302 (185-629) 
CpG 81.5 (10.1-209) 10.3 (4.95-32.4) 27.3 (4.85-10500) 59.4 (29.1-334) 
Basal expression of IL-6 (pg/mL) Relative expression of IL-6 (%) 
Medium 106 (10.9-1054) 34.9 (9.30-986) 0 0 
PGN 3780 (2300-631) 3660 (2828-5367) 2060 (470-3620) 1220 (455-4840) 
LPS 6700 (5517-9590) 8010(6924-9523) 3590(1860-5750) 5430 (3200-9490) 
Poly IC 266 (7.85-1186) 180(11.0-1329) -3.70 (-11.2-62.3) 43.9 (-5.40-73.5) 
ssRNA 370 (35.6-1468) 132(9.10-1469) -9.30 (-22.6-160) 10.9 (-6.00-137) 
Flagellin 6200 (4998-8217) 6340 (5719-7759) 1110(893-3260) 2690(1620-3960) 
R837 672 (169-3719) 328 (121-2887) 254 (64.6-1930) 174 (42.1-657) 
CpG 1410(37.7-4046) 124 (22.6-3057) 47.8 (-6.25-1190) 28.5 (13.7-97.2) 
Table 7.5 Expression of IL-1 p and IL-6 upon TLR lignad activation. 
Culture supernatant was obtained from PBMC cultured with medium and TLR ligands 
for 24 h. The basal and relative expression of IL-1 (3 and IL-6 by PBMC was analyzed 
by flow cytometry. Numerical data are expressed as median (IQR). Mann Whitney 
rank sum test was used to assess the differences of expression among SLE patients 
and control subjects (CTL). 
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CTL sTi CTL SLE 
Basal expression of CCL2 (pg/mL) Relative expression of CCL2 (%) 
Medium 1481 (666-4250) 939 (364-4960) 0 0 
PGN 3609 (2530-1190) 8812(3830-11600) 132 (-4.05-1670) 1010(318-3550) 
LPS 1519 (490-4060) 2320 (962-3170) -51.1 (-66.1-301) 90.5 (-15.1-285) 
Poly IC 2716 (809-3810) 1859(1140-9280) 50.6 (-4.05-172) 43.9 (-5.15-306) 
ssRNA 1979 (1320-4120) 3310(357-7880) 52.7 (-0.850-187) 43.0 (-31.8-573) 
Flagellin 3665 (2550-11200) 6074 (3910-8470) 133 (42.6-1110) 912 (68.0-1340) 
R837 3863 (2870-4990) 4330(2270-7410) 120 (12.2-610) 557 (235-1960) 
CpG 2588 (1990-3220) 3290 (864-8750) 47.5 (7.25-127) 41.6(9.10-392) 
Basal expression of CCL5 (pg/mL) Relative expression of CCL5 (%) 
Medium 455 (85.5-1430) 379 (44.1-506) 0 0 
PGN 867 (160-2120) 916(99.5-1200) 109 (12.5-267) 180(125-287) 
LPS 1030 (213-2890) 810(167-1890) 145 (57.3-495) 145 (125-391) 
Poly IC 775 (71.3-1160) 390 (38.1-1340) -0.90 (-22.3-85.9) -6.10 (-12.9-89.5) 
ssRNA 439 (72.2-2320) 597 (33.6-2340) 20.9 (-12.9-78.5) 25.3 (6.30-366) 
Flagellin 862 (318-2280) 685 (124-1500) 135 (20.0-311) 176 (48.5-266) 
R837 446(111-2260) 558 (51.2-881) 7.45 (-10.3-51.1) 60.4 (42.4-120) 
CpG 333 (70.7-1560) 470 (33.9-1110) -20.8 (-36.0-29.8) 25.6 (-10.2-70.9) 
Table 7.6 Expression of CCL2 and CCL5 upon TLR ligand activation. 
Culture supernatant was obtained from PBMC cultured with medium and TLR ligands 
for 24 h. The basal and relative expression of CCL2 and CCL5 by PBMC was 
analyzed by flow cytometry. Numerical data were expressed as median (IQR). Mann 
Whitney rank sum test was used to assess the differences of expression among SLE 
patients and control subjects (CTL). 
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CTL SLE CTL SLE 
Basal expression of CXCL8 (pg/mL) Relative expression of CXCL8 (%) 
Medium 9760 (1500-18900) 7175 (999-20500) 0 0 
PGN 19700 20170 543 (51.6-1670) 627 (57.3-2250) 
(18800-23400) (18900-22300) 
LPS 丨 9600 20540 426 (51.3-1690) 633 (59.7-2310) 
(19200-23200) (19100-22700) 
Poly IC 6480 (959-15400) 6606 (1110-16400) 19.1 (-0.550-116) 20.2 (-10.5-86.3) 
ssRNA 9520 (2360-16000) 6347 (1210-17300) 29.8 (2.45-396) 32.7 (-23.4-175) 
Flagellin 1990 20170 535 (46.0-1650) 653 (55.8-2360) 
(19300-22900) (19300-23000) 
R837 699 (2810-1770) 8386 (2680-17900) 49.9 (-15.8-457) 69.4(16.2-736) 
CpG 13700 (3610-18700) 7721 (2380-17900) 33.2 (9.30-477) 53.2(4.80-668) 
Basal expression of CXCLIO (pg/niL) Relative expression of CXCLIO (%) 
Medium 10.9 (9.72-48.8) 11.7(10.6-28.8) 0 0 
PGN 10.7 (10.4-39.3) 11.4(10.7-798) 6.00 (-3.20-13.0) 6.30(3.45-1010) 
LPS 12.3 (10.9-58.1) 11.7 (11.1-129) 17.5 (3.65-28.6) 6.50(0.900-129) 
Poly IC 11.7 (10.2-43.2) 12.6(11.6-50.5) 4.60 (-0.20-8.70) 6.60 (-4.25-28.0) 
ssRNA 11.3 (10.4-37.2) 12.3 (11.3-28.1) 2.30 (-7.10-9.15) 6.05 (-21.6-14.2) 
Flagellin 12.0(11.0-44.7) 12.3 (11.1-529) 7.00 (3.90-19.2) 10.8(4.60-851) 
R837 35.1 (11.6-109) 75.5 (12.5-294) 41.1 (16.7-638) 562 (219-974) 
CpG 11.7 (10.8-51.8) 11.7(11.1-39.7) 7.50 (-0.400-17.6) 7.00 (-4.80-14.5) 
Table 7.7 Expression of CXCL8 and CXCLIO upon TLR ligand activation. 
Culture supernatant was obtained from PBMC cultured with medium and TLR ligands 
for 24 h. The basal and relative expression of CXCL8 and CXCLIO by PBMC was 
analyzed by flow cytometry. Numerical data are expressed as median (IQR). Mann 
Whitney rank sum test was used to assess the differences of expression among SLE 
patients and control subjects (CTL). 
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7.4 Discussion 
Although the etiology of SLE has not been fully elucidated, it is generally 
regarded that the abnormality in monocytes and lymphocytes is the primary 
characteristic of the disease. Hyperactivity in monocytes, B and T lymphocytes can 
enhance antigen presentation, production of autoantibodies and inflammatory 
cytokines and chemokines, resulting in the amplification of the autoimmune response 
and exacerbation of the disease. Emerging evidence has reported that TLRs, which 
have been recognized as essential components in innate immunity, also participate in 
autoimmune responses. 
For better understanding the pathological role of TLRs in autoimmune disease, 
we examined the TLR expression profiles among SLE patients and control subjects. 
Our findings revealed that cell surface TLRs (TLR2, 4 and 5) were significantly 
increased in monocytes, CD4+ T lymphocytes, CD8+ T lymphocytes and CD 19+ B 
lymphocytes in SLE patients (Table 7.2). TLRl and 6, which form heterodimer with 
TLR2, also markedly increased in SLE patients (Table 7.2), and the expression was 
significantly correlated with TLR2 (data not shown). In addition, we observed that 
TLR4 expression was positively related with SLEDAI score in CD4+ T lymphocytes 
and CD8+ T lymphocytes, and TLR6 expression in CD 19+ B lymphocytes was also 
correlated with disease activity (Table 7.3). Our results was concurrent with the study 
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by Abdollahi-Roodsaz et al.’ which suggested that aberrant TLR4 expression may 
affect the skew the balance of T lymphocytes in mouse model of arthritis. Their 
findings confirmed that TLR4 deficient mice had markedly reduced numbers of Thl 7 
lymphocytes and lowered capacity to produce IL-17, which can subsequently 
exacerbate the autoinflammatory process of rheumatoid arthritis (RA) 
[Abdollahi-Roodsaz et al., 2008]. Study by Radstake et al. also reported that 
expression of TLR2 and TLR4 was significantly increased in inflamed synovium of 
RA patients, and the expression was positively associated with IL-12 and IL-18, but 
not with other cytokines [Radstake et al., 2004]. Therefore, they suggested that IL-12 
and IL-18 can increase the expression of TLR2 and TLR4 for aggravating 
autoimmune diseases [Radstake et al., 2004]. To support the hypothesis, study by 
Abdollahi-Roodsaz et al. also demonstrated that inhibition of TLR4 can suppress the 
severity of experimental arthritis and reduced IL-ip expression in arthritic joints 
[Abdollahi-Roodsaz et al., 2007]. In addition, Kattah et al. also reported that PBMCs 
stimulated with TLR4 or TLR8/7 lignads, but not in TLR2, 1, 5 and 6，can enhance 
the differentiation of Thl7 lymphocytes, and the stimulation is independent of 
coculture with antigen presenting cells (APCs). To further confirm the results, we 
have also performed a pilot study on the cytokine profile upon stimulation of TLR2 
and TLR4 by peptidoglycan (PGN) and lipopolysaccarides (LPS) respectively. From 
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our result, there is an observable increased in the relative expression IL-ip and IL-6 
upon LPS stimulation in SLE patients compared with control subjects (Table 7.5). 
However, the change is not statistically significant due to limited number of cases. 
Since IL-1 (3 and IL-6 are crucial for the differentiation of human Thl 7 lymphocytes, 
we suggest that overexpression of TLR4 may lead to the elevated expression of Thl7 
lymphocytes and exacerbate the autoinflammaotry process in SLE. Further 
investigation is required to confirm our results. 
In addition, TLRS was found to be elevated in SLE patients than control subjects; 
we therefore hypothesize that TLR5 may also participate in the manifestation of SLE. 
Based on the study by Didierlaurent et al., after stimulation with flagellin, TLRS 
could drive the MyD88-dependent Th2-type immunity in mice model, as exemplified 
by the elevated secretion of IL-4 and IL-13 by Th lymphocytes as well as IgGl 
responses. In addition, the expression of Thl-related cytokine IL-12 p70 was reduced 
upon flagellin stimulation [Didierlaurent et al., 2004]. Th2-mediated immune 
response is related with the autoantibodies production, which is a major characteristic 
of SLE. Therefore, we suggested that overexpression of TLRS may activate the 
Th2-mediated immune response, which in turn elevated the production of 
autoantibodies from memory and plasma B lymphocytes. From our pilot study, we 
also observed that the basal and relative expression of Th2-related cytokine, IL-10, 
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was up-regulated upon stimulation by flagellin, which further supported our 
hypothesis (Table 7.4). However, more investigations are required to confirm the 
results. 
Given that nucleic acids are the major component of SLE autoantigens, 
intracellular TLRs (TLRS, 7, 8 and 9) recognizing dsRNA, ssRNA, and unmethylated 
CpG DNA, have become the popular targets for the study of SLE. Christenseii et al. 
revealed that TLR9, which is responsible for the recognizing ummethylated CpG 
DNA, is required for the spontaneous generation of autoantibodies. In contrast, TLR7, 
recognizing ssRNA in mice, failed to generate antibodies against RNA-containing 
antigens such as Sm. In addition, they demonstrated that mice deficient in TLR9 had 
exacerbating autoimmune autoimmunity while the TLR7-defeicent mice had 
ameliorated disease, suggesting the divergent role of TLR9 and TLR7 in autoimmune 
diseases [Christensen et al.’ 2006]. Kwok et al. also demonstrated that pDCs 
stimulated with TLR9 ligand showed reduced level of IFN-a production in SLE 
patients. In addition, PBMC isolated from SLE patients exhibited higher expression of 
IFN-a signature genes, and was desensitized to TLR signaling [Kwok et al., 2008]. 
In contrast, Nakano et al. demonstrated that TLR9 was overexpressed on 
peripheral blood B lymphocytes from patients with active SLE, and the expression 
was correlated with SLEDAI. In addition, the production of anti-dsDNA antibody and 
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IL-10 was upregulated upon stimulation with CpG-ODN [Nakano et al., 2008]. 
Papadimitraki et al. also reported that the TLR9 expression plasma and memory B 
lymphocytes were increased in patients with active SLE, and the increased 
percentages of TLR9 expressing B lymphocytes were correlated with the presence of 
anti-dsDNA antibodies [Papadimitraki et al., 2006]. 
From our results, TLR9 expression was significantly elevated in monocytes, 
CD4+ T lymphocytes, CD8+ T lymphocytes and CD 19+ B lymphocytes of SLE 
patients, which was concurrent with the results of Nakano et al. However, the TLR7 
expression was not statistically difference among SLE patients and control subjects. 
Our findings were contradicted with the results from Komatsuda et al., which 
demonstrated that the mRNA expression of TLR7 was upregulated in SLE patients by 
real-time quantitative PCR [Komatsuda et aL, 2008]. Since gene expression does not 
necessarily reflect protein expression, the contradiction can be explained by the 
different method used in the detection of TLRs. 
We have also reported that TLRS, which recognize ssRNA in human, was 
significantly elevated in SLE patients than control subjects. Our results were in line 
with Peng et al” which reported that TLRS can mediate the reversal of the suppressive 
function of Treg lymphocytes, and the effect was independent of DCs but required 
functional TLR8-MyD88-IRAK4 signaling in Treg lymphocytes [Peng et al., 2005]. 
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Therefore, we suggested that the overexpression of TLR8 can suppress the function of 
Treg lymphocytes, leading to the exacerbating of SLE pathogenesis. Apart from TLR8 
and 9，the expression of TLR3 was also elevated on different lymphocyte subsets of 
SLE patients. As reported by Patole et al., viral dsRNA could stimulate TLR3 on 
glomerular mesangial cells and APCs to release IL-6, IL-12p70 and IFN-a, which 
aggravated autoimmune tissue injury [Patole et al.’ 2005]. Ittah et al. also 
demonstrated that dsRNA virus and poly IC promoted B cell activating factor (BAFF) 
mRNA and protein expression in cultured salivary gland epithelial cells. From the 
reports, we suggested that TLR3 may play a role in SLE pathogenesis by aggravating 
both APCs and B lymphocytes in SLE pathogenesis. The exact pathological 
mechanism, however, required further elucidation. 
In conclusion, our findings revealed that cell surface TLRs (TLRl, 2, 4，5 and 6), 
as well as intracellular TLRs (TLRS, 8 and 9) were significantly increased in the 
monocytes, CD4+ T lymphocytes, CD8+ T lymphocytes and CD 19+ B lymphocytes 
in SLE patients than control subjects. The overexpression of TLRs may result in 
aberrant activities in monocytes, T and B lymphocytes, which cause the increased 
expression of proinflammatory cytokines and autoantibodies in SLE patients. 
Apart from the monocytes and lymphocytes, dendritic cells (DC) are also 
important mediators of TLR interaction with microbial ligands. After encountered 
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with PAMP, DC was activated through TLR, resulting in maturation and induction of 
inflammatory cytokines [Kaisho et al., 2001]. Two common groups of DCs have been 
identified. The mDC, which is myeloid derived, are characterized by the expression of 
CDl lc , HLA DR, GM-CSFR, CD13, and CD33，and alack of expression of IL-3R 
(CD 123). The pDC, which is plasmacytoid derived, is characterized by the high 
expression CD123, and lacking CDl lc on the cell surface [Rissoan et al., 1999]. The 
role of mDC and pDC in SLE, however, has not been fully elucidated. In order to 
expand our study, we will measure the TLRs expression in mDC and pDC in SLE 
patients. Our results can therefore further elucidate the underlying roles of TLRs in 
SLE pathogenesis and shed light in the development of therapeutic target in the near 
future. 
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Chapter 8 
Conclusion and Future Perspectives 
SLE is a prototypic systemic autoimmune disease characterized by various 
immunological abnormalities, including dysregulated activation of both T and B 
lymphocytes with the production of large quantity of autoreactive antibodies. 
However, the immunopathological mechanism has not been fully elucidated. 
In our present study, we have demonstrated a significant increase in the plasma 
concentration of B cell chemokine CXCL13 in SLE patients, and the expression was 
positively correlated with disease severity. We also found that plasma CXCL13 
concentrations in SLE patients did not show any correlation with the dosages of 
prednisolone, hydroxychloroquine and azathioprine. In addition, it has been recently 
reported that TNF-a plays a crucial role in the recruitment and maturation of dendritic 
cells (DC) into CXCL13 producing DC during the development of SLE [Ishikawa et 
al.’ 2002; Ishikawa et al., 2007]. Therefore, we have measured the plasma level of 
TNF-a in peripheral blood of SLE patients as well as their gene expression level in 
PBMC. However, the concentration of TNF-a in plasma was below detection limit, 
and the gene expression level of human TNF-a in PBMC of SLE patients was not 
significantly different from normal controls. Since local consumption and degradation 
of TNF-a by the inflamed tissue may account for the low expression level of TNF-a 
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in the peripheral blood, we measured the plasma concentration of soluble TNF 
Receptor 1 (sTNFRl) in plasma, and it was confirmed that sTNFRl was significantly 
increased in SLE patients. However, our results are insufficient to explain the aberrant 
TNF-a-mDC-CXCLl3-B cell axis. Further elucidation on the ex vivo production of 
CXCL13 and BAFF by peripheral niDC upon TNF-a stimulation, and also the 
expression of CXCL13 receptor (CXCR5) on B lymphocytes upon TNF-a activation 
is required to understand the TNF-a-mDC-CXCLl 3-B cell axis. 
In the second part of our study, we investigated the expression of CD26, a T cell 
co-stimulatory molecule and dipeptidyl peptidase IV, in SLE. Although no significant 
difference between plasma concentrations of soluble CD26 in SLE patients and 
control subjects, there was significant down-regulation in the cell number of iNKT 
lymphocytes and the cell surface expression of CD26 on Th and iNKT lymphocyte of 
SLE patients. Based on our results, we suggested that the down-regulation of CD26 
can shift the conventional T lymphocyte toward a Thl-biased response and exacerbate 
SLE disease development. In the near future, we are going to assess the correlation 
between the expressions of soluble or cell surface CD26 and the plasma concentration 
of Thl-related chemokine CXCLIO in SLE patients peripheral blood. Through this 
follow-up study, we should have a better understanding of the effect of CD26 in 
Thl-related inflammatory responses. 
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For the third part of our study, we explored the role of Thl 7 lymphocytes and the 
expression of IL-17 in SLE. Our results revealed that SLE patients express 
significantly higher number of Thl7 lymphocytes than that in control subjects. Upon 
IL-23 activation, the co-stimulated PBMC responded with an aberrant ex vivo 
production of IL-17A and the increase was significantly higher in SLE patients than 
controls. Our results demonstrated direct involvement of IL-23 in the IL-23/IL-17 
inflammatory axis, which acts to induce the distinct T cell population that produces 
IL-17 as the effector cytokine for promoting the autoinflammatory responses in SLE. 
In this study, we have also applied our well-established intracellular staining 
technique with subsequent flow cytometric analysis to elucidate the intracellular 
MAPK cascades for the activation of different leukocyte subsets including CD4+T 
lymphocytes, CD8+T lymphocytes, CD19+B lymphocytes and monocytes in SLE. 
Our results demonstrated that the expression of phospho-p38 MAPK was significantly 
increased in CD4+, CD8+ and CD 19+ lymphocytes of SLE patients than control 
subjects. Apart from the p38 MAPK signaling pathway, we have also found out that 
the expression of phospho-JNK was significantly elevated in CD4+，CD8+ and 
CD 19+ lymphocytes of SLE patients upon ex vivo activation of inflammatory 
cytokine IL-18. In addition, the expression of phospho-JNK in IL-18 activated CD8+ 
lymphocytes, and the relative percentage increase of phospho-JNK expression in 
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CD 19+ lymphocytes after IL-18 activation was positively correlated with SLEDAI. 
However, no significant difference was observed for the expression of phospho-ERK 
in resting or IL-18 activated monocytes and lymphocytes between SLE patients and 
control subjects. From our results, we suggested that the differential activation of 
intracellular p38-MAPK and JNK signaling pathways can be the underlying 
intracellular mechanisms causing lymphocyte hyperactivity in SLE. Apart from the 
MAPK signaling pathways, we are also interested in the role of transcription factors 
such as nuclear factor kappa B (NF-kB) and the counteracting molecule, inhibitory 
kappa B (IkB) in the pathogenesis of SLE. Therefore, we will do a follow-up 
experiment in the near future. 
Finally, we have measured the differential expression of TLRl to TLR9 in 
leukocyte subsets of SLE. Our results have demonstrated that the expression of 
intracellular TLRs (TLR 3’ 8’ 9) and cell surface TLRs (TLR 1，2，4, 5 and 6) were 
significantly elevated in monocytes, CD4+, CD8+ and CD 19+ lymphocytes in SLE. 
In addition, the expression of TLR4 in CD4+ and CD8+ lymphocytes, together with 
the expression of TLR6 in CD 19+ lymphocytes, were significantly correlated with 
SLEDAI. The aberrant expression of the TLRs may cause hyperactivity in monocytes 
and lymphocytes, particularly during infection-mediated innate immune response, 
which resulted in the exacerbation of SLE. Apart from monocytes and lymphocytes, 
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TLRs also participate in dendritic cell (DC) activation and maturation, resulting in the 
expression of inflammatory cytokines. We would like to expand our study by 
elucidating the expression of TLRl to TLR9 on two major types of DC: myeloid DC 
(mDC) and plasmacytoid DC (pDC) in the coming future. 
In conclusion, our study investigated the immunopathogenesis of SLE by 
assessing the activation of monocytes, T and B lymphocytes upon stimulation of 
various stimuli, and also the underlying intracellular signaling mechanisms. Further 
investigation on the expanding cytokines and chemokines family on the manifestation 
of the disease are still on progress. Our findings should enhance the understanding of 
the immunopathology of SLE and facilitate better approaches for potential therapies 




Table 1: Criteria and weight for the assessment of SLEDAI score. 
(Modified from Bombardier et al” 1992) 
Weight Descriptor Definition 
8 Seizure Recent onset. Exclude metabolic, infectious or drug 
causes. 
8 Psychosis Altered ability to function in normal activity due to 
severe disturbance in the perception of reality. Include 
hallucinations, incoherence, marked loose associations, 
impoverished thought content, marked illogical 
thinking, bizarre, disorganized, or catatonic behavior. 
Exclude uremia and drug causes. 
8 Organic brain Altered mental function with impaired orientation, 
syndrome memory, or other intellectual function, with rapid onset 
and fluctuating clinical features. Include clouding of 
consciousness with reduced capacity to focus, and 
inability to sustain attention to environment, plus at 
least 2 of the following: perceptual disturbance, 
incoherent speech, insomnia or daytime drowsiness, or 
increased or decreased psychomotor activity. Exclude 
metabolic, infectious, or drug causes. 
8 Visual Retinal changes of SLE. Include cytoid bodies, retinal 
disturbance hemorrhages, serous exudate or hemorrhages in the 
choroid, or optic neuritis. Exclude hypertension, 
infection, or drug causes. 
8 Cranial nerve New onset of sensory or motor neuropathy involving 
disorder cranial nerves. 
8 Lupus headache Severe, persistent headache; may be migrainous, but 
must be nonresponsive to narcotic analgesia. 
8 CVA New onset of cerebrovascular accident(s). Exclude 
arteriosclerosis. 
8 Vasculitis Ulceration, gangrene, tender finger nodules, periungual 
infarction, splinter hemorrhages, or biopsy or 
angiogram proof of vasculitis. 
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4 Arthritis More than 2 joints with pain and signs of inflammation 
(i.e.，tenderness, swelling, or effusion). 
4 Myositis Proximal muscle aching/weakness, associated with 
elevated creatine phosphokinase/aldolase or 
electromyogram changes or a biopsy showing myositis. 
4 Urinary casts Heme-granular or red blood cell casts. 
4 Hematuria >5 red blood cellshigh power field. Exclude stone, 
infection, or other cause. 
4 Proteinuria >0.5 gm/24 hours. New onset or recent increase of 
more than 0.5 gm/24 hours 
4 Pyuria >5 white blood cellshigh power field. Exclude 
infection. 
2 New rash New onset or recurrence of inflammatory type rash. 
2 Alopecia New onset or recurrence of abnormal, patchy or diffuse 
loss of hair. 
2 Mucosal ulcers New onset or recurrence of oral or nasal ulcerations. 
2 Pleurisy Pleuritic chest pain with pleural rub or effusion, or 
pleural thickening. 
2 Pericarditis Pericardial pain with at least 1 of the following: rub, 
effusion, or electrocardiogram or echocardiogram 
confirmation. 
2 Low Decrease in CHSO, C3, or C4 below the lower limit of 
complement normal for testing laboratory. 
2 Increased DNA >25% binding by Fair assay or above normal range for 
binding testing laboratory. 
1 Fever �38°C. Exclude infectious cause. 
1 Thrombocytope <100,000 platelets/mm^ 
nia 
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